<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2202210536
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Xelobine
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Capecitabine
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        853.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Capecitabine Tablets belongs to the group of medicines called &quot;cytostatic medicines&quot;, which stop the growth of cancer cells. Capecitabine Tablets contains Capecitabine, which itself is not a cytostatic medicine. Only after being absorbed by the body is it changed into an active anti- cancer medicine (more in tumour tissue than in normal tissue).</p><p>Capecitabine Tablets is used in the treatment of colon, rectal, gastric, or breast cancers. Furthermore, Capecitabine Tablets is used to prevent new occurrence of colon cancer after complete removal of the tumour by surgery.</p><p>Capecitabine Tablets may be used either alone or in combination with other medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp; if you are allergic to Capecitabine or any of the other ingredients of this medicine (listed in Section 6). You must inform your doctor if you know that you have an allergy or over-reaction to this medicine,</p><p>&bull;&nbsp; if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer Medicines such as fluorouracil),</p><p>&bull;&nbsp; if you are pregnant or breast-feeding,</p><p>&bull;&nbsp; if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia),</p><p>&bull;&nbsp; if you have severe liver or kidney problems,</p><p>&bull;&nbsp; if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD)</p><p>&bull;&nbsp; if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster (chickenpox or shingles) therapy.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Capecitabine Tablets</p><p>&bull;&nbsp; if you know that you have a partial deficiency in the activity of the enzyme dihydropyrimidine dehydrogenase (DPD)</p><p>&bull;&nbsp; if you have liver or kidney diseases</p><p>&bull;&nbsp; if you have or had heart problems (for example an irregular heartbeat or pains to the chest, jaw and back brought on by physical effort and due to problems with the blood flow to the heart)</p><p>&bull;&nbsp; if you have brain diseases (for example, cancer that has spread to the brain, or nerve damage (Neuropathy)</p><p>&bull;&nbsp; if you have calcium imbalances (seen in blood tests)</p><p>&bull;&nbsp; if you have diabetes</p><p>&bull;&nbsp; if you cannot keep food or water in your body because of severe nausea and vomiting</p><p>&bull;&nbsp; if you have diarrhoea</p><p>&bull;&nbsp; if you are or become dehydrated</p><p>&bull;&nbsp; if you have imbalances of ions in your blood (electrolyte imbalances, seen in tests)</p><p>&bull;&nbsp; if you have a history of eye problems as you may need extra monitoring of your eyes</p><p>&nbsp;</p><p>&bull;&nbsp; if you have a severe skin reaction.</p><p><strong>DPD deficiency</strong>: DPD deficiency is a rare condition present at birth that is not usually associated with health problems unless you receive certain medicines. If you have an unrecognised DPD deficiency and take Capecitabine Tablets, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 possible side effects. Contact your doctor immediately if you are concerned about any of the side effects or if you notice any additional side effects not listed in the leaflet (see section 4 possible side effects).</p><p>Children and Adolescents:</p><p>Capecitabine Tablets is not indicated in children and adolescents. Do not give Capecitabine Tablets to children and adolescents</p><p>Other medicines and Capecitabine Tablets</p><p>Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is extremely important, as taking more than one medicine at the same time can strengthen or weaken the effect of the medicines.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:64.5pt;margin-top:12.45pt;width:456.8pt;height:104pt;z-index:-251658240;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:5.05pt;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt;text-align:justify;
     line-height:150%'>You must not take brivudine (an anti-viral medicines for
     treatment of shingles or chickenpox) at the same time as Capecitabine
     treatment (including during any rest periods when you are not taking any
     Capecitabine tablets).<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:5.15pt;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt;text-align:justify;
     line-height:150%'>If you have taken brivudine you must wait for at least 4
     weeks after stopping brivudine before starting to take Capecitabine. See
     also section “Do not take Capecitabine Tablets”.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="613" height="143" alt="Text Box: You must not take brivudine (an anti-viral medicines for treatment of shingles or chickenpox) at the same time as Capecitabine treatment (including during any rest periods when you are not taking any Capecitabine tablets).
If you have taken brivudine you must wait for at least 4 weeks after stopping brivudine before starting to take Capecitabine. See also section “Do not take Capecitabine Tablets”.
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>Also, you need to be particularly careful if you are taking any of the following:</p><p>&bull;&nbsp; Gout medicines (allopurinol),</p><p>&bull;&nbsp; blood-thinning medicines (coumarin, warfarin),</p><p>&bull;&nbsp; medicines for seizures or tremors (phenytoin),</p><p>&bull;&nbsp; Interferon alpha,</p><p>&bull;&nbsp; radiotherapy and certain medicines used to treat cancer (folinic acid, oxaliplatin, bevacizumab, Cisplatin, Irinotecan),</p><p>&bull;&nbsp; medicines used to treat folic acid deficiency.</p><p>Capecitabine Tablets with food and drink</p><p>You should take Capecitabine Tablets no later than 30 minutes after meals</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You must not take Capecitabine Tablets if you are pregnant or think you might be.</p><p>You must not breast-feed if you are taking Capecitabine Tablets</p><p>Driving and Using Machines</p><p>Capecitabine Tablets may make you feel dizzy, nauseous or tired. It is therefore possible that Capecitabine Tablets could affect your ability to drive a car or operate machines.</p><p>Capecitabine Tablets contains anhydrous lactose</p><p>If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Capecitabine Tablets should only be prescribed by a doctor experienced in the use of anticancer medicines.</p><p>Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of Capecitabine Tablets is based on your body surface area. This is calculated from your height and weight. The usual dose for adults is 1250 mg/m2 of body surface area taken two times daily (morning and evening). Two examples are provided here: A person whose body weight is 64 kg and height is 1.64 m has a body surface area of 1.7 m2 and should take 4 tablets of 500 mg and 1 tablet of 150 mg two times daily. A person whose body weight is 80 kg and height is 1.80 m has a body surface area of 2.00 m2 and should take 5 tablets of 500 mg two times daily</p><p>Your doctor will tell you what dose you need to take, when to take it and for how long you need to take it.</p><p>Your doctor may want you to take a combination of <em>150 mg </em>and <em>500 mg </em>tablets for each dose.</p><p>&bull;&nbsp; Take the tablets <strong>morning and evening </strong>as prescribed by your doctor.</p><p>&bull;&nbsp;&nbsp; Take the tablets within <strong>30 minutes after the end of a meal </strong>(breakfast and dinner) <strong>and Swallow whole with water.</strong></p><p>&bull;&nbsp; It is important that you take all your medicine as prescribed by your doctor.</p><p>Capecitabine Tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets are taken). This 21 day period is one treatment cycle.</p><p>&nbsp;</p><p>In combination with other medicines the usual dose for adults may be less than 1250 mg/m2 of body surface area, and you may need to take the tablets over a different time period (e.g. every day, with no rest period).</p><p>If you take more Capecitabine Tablets than you should</p><p>If you take more Capecitabine Tablets than you should, contact your doctor as soon as possible before taking the next dose.</p><p>You might get the following side effects if you take a lot more Capecitabine than you should: feeling or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds of blood cells). Tell your doctor immediately if you experience any of these symptoms.</p><p>If you forget to take Capecitabine Tablets</p><p>Do not take the missed dose at all. Do not take a double dose to make up for a forgotten dose. Instead, continue your regular dosing schedule and check with your doctor.</p><p>If you stop taking Capecitabine Tablets</p><p>There are no side effects caused by stopping treatment with Capecitabine. In case you are using Coumarin anticoagulants (containing e.g. phenprocoumon), stopping Capecitabine might require that your doctor adjusts your anticoagulant dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>STOP </strong>taking Capecitabine Tablets immediately and contact your doctor if any of these symptoms occur:</p><p>&bull;&nbsp; <strong><em>Diarrhoea</em></strong>: if you have an increase of 4 or more bowel movements compared to your normal bowel movements each day or any diarrhoea at night.</p><p>&bull;&nbsp; <strong><em>Vomiting</em></strong>: if you vomit more than once in a 24-hour time period.</p><p>&bull;&nbsp; <strong><em>Nausea: </em></strong>if you lose your appetite, and the amount of food you eat each day is much less than Usual.</p><p>&bull;&nbsp; <strong><em>Stomatitis</em></strong>: if you have pain, redness, swelling or sores in your mouth and/or throat.</p><p>&bull;&nbsp; <strong><em>Hand-and-foot skin-reaction: </em></strong>if you have pain, swelling, redness or tingling of hands and/or feet.</p><p>&bull;&nbsp; <strong><em>Fever: </em></strong>if you have a temperature of 38&deg;C or greater.</p><p>&nbsp;</p><p>&bull;&nbsp; <strong><em>Infection</em></strong>: if you experience signs of infection caused by bacteria or virus, or other organisms.</p><p>&bull;&nbsp; <strong><em>Chest pain</em></strong><em>: </em>if you experience pain localised to the centre of the chest, especially if it occurs During exercise<em>.</em></p><p>&bull;&nbsp;&nbsp; <strong><em>Steven-Johnson syndrome: </em></strong>if you experience painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.</p><p>&bull;&nbsp; <strong><em>DPD Deficiency</em></strong>: if you have a known DPD deficiency, you are at an increased risk of acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by Capecitabine Tablets (e.g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and neurotoxicity).</p><p>If caught early, these side effects usually improve within 2 to 3 days after treatment discontinuation. If these side effects continue, however, contact your doctor immediately. Your doctor may instruct you to restart treatment at a lower dose.</p><p>Hand and foot skin-reaction can lead to loss of fingerprint, which could impact your identification by finger print scan.</p><p>In addition to the above, when Capecitabine Tablets is used alone, very common side effects, which may affect more than 1 in 10 people are:</p><p>&bull;&nbsp; abdominal pain</p><p>&bull;&nbsp; rash, dry or itchy skin</p><p>&bull;&nbsp; tiredness</p><p>&bull;&nbsp; loss of appetite (anorexia)</p><p>These side effects can become severe; therefore, it is important that you <strong>always contact your doctor immediately </strong>when you start to experience a side effect. Your doctor may instruct you to decrease the dose and/or temporarily discontinue treatment with Capecitabine Tablets . This will help reduce the likelihood that the side effect continues or becomes severe.</p><p>Other side effects are:</p><p><strong>Common side effects (may affect up to 1 in 10 people) include:</strong></p><p>&bull;&nbsp; decree</p><p>ses in the number of white blood cells or red blood cells (seen in tests)</p><p>&bull;&nbsp; Dehydration, weight loss</p><p>&bull;&nbsp; sleeplessness (insomnia), depression</p><p>&bull;&nbsp; Headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling Sensation), taste changes</p><p>&bull;&nbsp; eye irritation, increased tears, eye redness (conjunctivitis)</p><p>&bull;&nbsp; Inflammation of the veins (thrombophlebitis),</p><p>&bull;&nbsp; shortness of breath, nose bleeds, cough, runny nose</p><p>&bull;&nbsp; Cold sores or other herpes infections</p><p>&bull;&nbsp; Infections of the lungs or respiratory system (e.g. pneumonia or bronchitis)</p><p>&bull;&nbsp; bleeding from the gut, constipation, pain in upper abdomen, indigestion, excess wind, dry mouth</p><p>&bull;&nbsp; skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin discolouration, skin loss, skin inflammation, nail disorder</p><p>&bull;&nbsp; pain in the joints, or in the limbs (extremities), chest or back</p><p>&bull;&nbsp; fever, swelling in the limbs, feeling ill</p><p>&bull;&nbsp; problems with liver function (seen in blood tests) and increased blood bilirubin (excreted by the liver)</p><p>Uncommon side effects (may affect up to 1 in 100 people) include:</p><p>&bull;&nbsp; blood infection, urinary tract infection, infection of the skin, infections in the nose and throat, fungal infections (including those of the mouth), influenza, gastroenteritis, tooth abscess,</p><p>&bull;&nbsp; lumps under the skin (lipoma)</p><p>&bull;&nbsp; decreases in blood cells including platelets, thinning of blood (seen in tests)</p><p>&bull;&nbsp; allergy</p><p>&bull;&nbsp; diabetes, decrease in blood potassium, malnutrition, increased blood triglycerides</p><p>&bull;&nbsp; confusional state, panic attacks, depressed mood, decreased libido</p><p>&bull;&nbsp; difficulty speaking, impaired memory, loss of movement coordination, balance disorder, fainting, nerve damage (neuropathy) and problems with sensation</p><p>&bull;&nbsp; blurred or double vision</p><p>&bull;&nbsp; vertigo, ear pain</p><p>&bull;&nbsp; irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)</p><p>&bull;&nbsp; blood clots in the deep veins, high or low blood pressure, hot flushes, cold limbs (extremities), purple spots on the skin</p><p>&bull;&nbsp; blood clots in the veins in the lung (pulmonary embolism), collapsed lung, coughing up blood, asthma, shortness of breath on exertion</p><p>&bull;&nbsp; bowel obstruction, collection of fluid in the abdomen, inflammation of the small or large intestine, the stomach or the oesophagus, pain in the lower abdomen, abdominal discomfort, heartburn (reflux of food from the stomach), blood in the stool</p><p>&bull;&nbsp; jaundice (yellowing of skin and eyes)</p><p>&bull;&nbsp; skin ulcer and blister, reaction of the skin with sunlight, reddening of palms, swelling or pain of the face</p><p>&bull;&nbsp; joint swelling or stiffness, bone pain, muscle weakness or stiffness</p><p>&bull;&nbsp; fluid collection in the kidneys, increased frequency of urination during the night, incontinence, blood in the urine, increase in blood creatinine (sign of kidney dysfunction)</p><p>&bull;&nbsp; unusual bleeding from the vagina</p><p>&bull;&nbsp; swelling (oedema), chills and rigors</p><p>Some of these side effects are more common when Capecitabine is used with other medicines for the treatment of cancer. Other side-effects seen in this setting are the following:</p><p>Common side effects (may affect up to 1 in 10 people) include:</p><p>&bull;&nbsp; Decrease in blood sodium, magnesium or calcium, increase in blood sugar</p><p>&bull;&nbsp; nerve pain</p><p>&bull;&nbsp; ringing or buzzing in the ears (tinnitus), loss of hearing</p><p>&bull;&nbsp; Vein inflammation</p><p>&bull;&nbsp; hiccups, change in voice</p><p>&bull;&nbsp; pain or altered/abnormal sensation in the mouth, pain in the jaw</p><p>&bull;&nbsp; Sweating, night sweats</p><p>&bull;&nbsp; Muscle spasm</p><p>&bull;&nbsp; Difficulty in urination, blood or protein in the urine</p><p>&bull;&nbsp; Bruising or reaction at the injection site (caused by medicines given by injection at the same time)</p><p>Rare side effects (may affect up to 1 in 1,000 people) include:</p><p>&bull;&nbsp; narrowing or blockage of tear duct (lacrimal duct stenosis)</p><p>&bull;&nbsp; liver failure</p><p>&bull;&nbsp; Inflammation leading to dysfunction or obstruction in bile secretion (cholestatic hepatitis)</p><p>&bull;&nbsp; Specific changes in the electrocardiogram (QT prolongation)</p><p>&bull;&nbsp; certain types of arrhythmia (including ventricular fibrillation, torsade de pointes, and bradycardia)</p><p>&bull;&nbsp; eye inflammation causing eye pain and possibly eyesight problems</p><p>&bull;&nbsp; Inflammation of the skin causing red scaly patches due to an immune system illness</p><p>Very rare side effects (may affect up to 1 in 10,000 people) include:</p><p>&bull;&nbsp; severe skin reaction such as skin rash, ulceration and blistering which may involve ulcers of The mouth, nose, genitalia, hands, feet and eyes (red and swollen eyes)</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong><em>&nbsp;&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Capecitabine Tablets contains </strong>The active substance is Capecitabine. <strong><u>Capecitabine Tablets USP 150mg:</u></strong></p><p>Each film coated tablet contains 150 mg of Capecitabine USP.</p><p><strong><u>Capecitabine Tablets USP 150mg:</u></strong></p><p>Each film coated tablet contains 500 mg of Capecitabine USP</p><p>The other ingredients are: Hypromellose 2910 5cps (Methocel E5 LV Premium), Microcrystalline cellulose (Avicel PH 112), Anhydrous Lactose (Super tab 21 AN), Croscarmellose Sodium (Ac- Di-Sol), Magnesium stearate, Purified water.</p><p>film Coating Composition<strong>: </strong>HPMC 2910/ Hypromellose, Titanium Dioxide, Iron oxide red, Iron oxide yellow Talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Capecitabine Tablets looks like? Capecitabine Tablets USP 150mg:

Light peach colored, capsule shaped, biconvex, film coated tablets debossed with '6' on one side and 'H' on the other side.

Capecitabine Tablets USP 500mg:

Peach colored, Oval shaped, biconvex, film coated tablets debossed with '3' on one side and 'H' on the other side.

How supplied:

Capecitabine Tablets are supplied in Blister pack

Capecitabine Tablets USP 150mg - Box of 30 blister tablets (6 x 10’s) Capecitabine Tablets USP 500mg - Box of 30 blister tablets (6 x 10’s) Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June, 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي اكسيلوباين أقراص على المادة الفعالة كابيسيتابين.</p><p dir="RTL">تنتمي اكسيلوباين أقراص إلى مجموعة الأدوية المسماة &quot;الأدوية المثبطة للخلايا&quot;، والتي توقف نمو الخلايا السرطانية. يحتوي اكسيلوباين أقراص على كابيسيتابين، وهو في حد ذاته ليس دواء لتثبيط الخلايا. ولكنه يتحول بعد أن يمتصه الجسم إلى دواء فعال لمكافحة السرطان (بنسبة أكثر في أنسجة الورم أكثر من الأنسجة الطبيعية).</p><p dir="RTL">يستخدم اكسيلوباين أقراص في علاج سرطان القولون والمستقيم والمعدة أو سرطان الثدي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال اكسيلوباين أقراص:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه مادة كابيسيتابين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6). فيجب عليك إبلاغ طبيبك إذا كنت تعرف أن لديك حساسية لهذا الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت مسبقا من حساسية شديدة للعلاج بالفلوريوبيريدين (مجموعة من مضادات السرطان مثل فلورويوراسيل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً أو مرضعة،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مستويات منخفضة للغاية من الخلايا البيضاء أو الصفائح الدموية في الدم (قلة الكريات البيضاء، قلة العدلات) أو نقص الصفيحات)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في الكبد أو الكلى،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرف أنه ليس لديك أي نشاط لإنزيم ثنائي هيدرو بيريميدين هيدروجيناز (DPD)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعالَج الآن أو عولجت في الأسابيع الأربعة الماضية باستخدام بريفودين كعلاج لحالة الهربس النطاقي (جدري الماء أو القوباء المنطقية) العلاج.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول اكسيلوباين أقراص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرف أن لديك نقص جزئي في نشاط إنزيم ثنائي هيدرو بيريميدين هيدروجيناز (DPD)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض الكبد أو الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب (مثل عدم انتظام ضربات القلب أو آلام في الصدر والفك والظهر بسبب الجهد البدني وبسبب مشاكل في تدفق الدم إلى القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض الدماغ (على سبيل المثال، السرطان الذي انتشر إلى المخ، أو تلف الأعصاب (الاعتلال العصبي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اختلالات في نسبة الكالسيوم (التي تظهر في اختبارات الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض السكري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تستطيع الاحتفاظ بالطعام أو الماء في جسمك بسبب الغثيان والقيء الشديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الجفاف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اختلالات في أيونات الدم (اختلال التوازن بالكهرباء، كما هو مثبت بالاختبارات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مسبق من مشاكل بالعين، فقد تحتاج إلى مراقبة إضافية لعينيك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك رد فعل تحسسي شديد على الجلد.</p><p dir="RTL"><strong>نقص إنزيم ثنائي هيدرو بيريميدين هيدروجيناز (</strong><strong>DPD</strong><strong>):</strong></p><p dir="RTL">&nbsp;نقص إنزيم DPD هي حالة نادرة توجد منذ الولادة وعادة لا ترتبط بالمشاكل الصحية إلا إذا تناولت أدوية معينة. إذا كان لديك نقص DPD غير معروف وتناولت اكسيلوباين أقراص، فأنت في خطر متزايد للإصابة المبكرة بأشكال حادة من الآثار الجانبية المدرجة في القسم 4 من الآثار الجانبية المحتملة. اتصل بطبيبك على الفور إذا كنت قلقًا بشأن أي من الآثار الجانبية أو إذا لاحظت أي آثار جانبية إضافية غير مدرجة في النشرة (انظر القسم 4 من الآثار الجانبية المحتملة).</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">اكسيلوباين أقراص غير مخصصة للاستخدام في الأطفال والمراهقين. فلا تعطي اكسيلوباين أقراص للأطفال والمراهقين</p><p dir="RTL"><strong>تناول أدوية أخرى مع اكسيلوباين أقراص </strong></p><p dir="RTL">قبل البدء في العلاج، أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى. هذا مهم جدا، حيث إن تناول أكثر من دواء في نفس الوقت يمكن أن يقوي أو يضعف تأثير الأدوية.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يجب ألا تتناول البريفودين (من الأدوية المضادة للفيروسات لعلاج القوباء المنطقية أو جدري الماء) في نفس الوقت أثناء العلاج بتناول اكسيلوباين أقراص (بما في ذلك خلال أي فترات انقطاع عندما لا تتناول أي جرعات من اكسيلوباين أقراص).</p><p dir="RTL">إذا كنت قد تناولت البريفودين، يجب عليك الانتظار لمدة 4 أسابيع على الأقل بعد إيقاف البريفودين وقبل البدء في تناول اكسيلوباين أقراص. انظر أيضًا القسم &quot;لا تتناول اكسيلوباين أقراص &quot;.</p></td></tr></tbody></table><p dir="RTL">ويجب أيضًا الحذر بشكل خاص إذا كنت تتناول أيًا مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية النقرس (ألوبيورينول)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية سيولة الدم (الكومارين، الوارفارين)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية النوبات أو الهزات (الفينيتوين)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انترفيرون ألفا،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج الإشعاعي وبعض الأدوية المستخدمة لعلاج السرطان (حمض الفوليني، أوكسالبلاتين، بيفاسيزوماب، سيسبلاتين، إرينوتيكان)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج نقص حمض الفوليك.</p><p dir="RTL"><strong>تناول اكسيلوباين أقراص مع الطعام والشراب</strong></p><p dir="RTL">يجب أن تتناول اكسيلوباين أقراص في موعد لا يتجاوز 30 دقيقة بعد وجبات الطعام.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء. يجب عدم تناول هذا الدواء أثناء الحمل أو في مرحلة الرضاعة الطبيعية أو التخطيط للرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">اكسيلوباين أقراص قد تجعلك تشعر بالدوار أو الغثيان أو التعب. لذلك من الممكن أن تؤثر اكسيلوباين أقراص على قدرتك على قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL"><strong>محتوى اكسيلوباين أقراص من اللاكتوز اللامائي</strong></p><p dir="RTL">إذا أخبرك طبيبك بأنك لديك مشكله تجاه تناول بعض السكريات، فاتصل بطبيبك قبل تناول هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك الطبيب أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">يجب أن يتم وصف اكسيلوباين أقراص فقط من قبل طبيب من ذوي الخبرة في استخدام الأدوية المضادة للسرطان.</p><p dir="RTL">سيقوم طبيبك بوصف الجرعة العلاجية المناسب لك. وتعتمد جرعة اكسيلوباين أقراص على مساحة سطح الجسم. ويتم حسابها من خلال بيانات الطول والوزن. الجرعة المعتادة للبالغين هي 1250 ملغم / م <sup>2</sup> من مساحة سطح الجسم يتم تناولها على مرتين يوميًا (الصباح والمساء). فيما يلي مثالان: الشخص الذي يبلغ وزن جسمه 64 كجم ويبلغ طوله 1.64 مترًا تبلغ مساحة سطح الجسم 1.7 م <sup>2</sup> ويجب أن يتناول 4 أقراص من 500 ملغم و1 قرص من 150 ملغم مرتين يوميًا. الشخص الذي يبلغ وزن جسمه 80 كيلوجرامًا ويبلغ ارتفاعه 1.80 مترًا، وتبلغ مساحته الجسمية 2.00 م <sup>2،</sup> ويجب أن يتناول 5 أقراص كل منها 500 ملغم مرتين يوميًا</p><p dir="RTL"><strong>سيخبرك طبيبك بالجرعة التي يجب أن تتناولها ومتى يجب عليك أن تتناولها والفترة التي ستستمر في تناوله خلالها.</strong></p><p dir="RTL">قد يرغب طبيبك في أن تتناول مزيج من أقراص 150 ملغم و500 ملغم لكل جرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تناول أقراص <strong>الصباح والمساء</strong> على النحو الذي يحدده الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تناول الأقراص في غضون 30 دقيقة بعد نهاية الوجبة (الإفطار والعشاء) <strong>ويتم الابتلاع مع الماء.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم أن تتناول كل الأدوية التي يصفها لك الطبيب.</p><p dir="RTL">عادة يتم تناول اكسيلوباين أقراص لمدة 14 يومًا تليها فترة راحة لمدة 7 أيام (لا يتم تناول أقراص خلالها). وهذه الفترة المكونة من 21 يوما هي دورة علاج واحدة.</p><p dir="RTL">بالاقتران مع الأدوية الأخرى، قد تكون الجرعة المعتادة للبالغين أقل من 1250 ملغم / م <sup>2</sup> من مساحة سطح الجسم، وقد تحتاج إلى تناول الأقراص على فترة زمنية مختلفة (على سبيل المثال، كل يوم، مع عدم وجود فترة راحة).</p><p dir="RTL"><strong>الجرعة الزائدة من اكسيلوباين أقراص</strong></p><p dir="RTL">إذا تناولت أكثر من الجرعة الموصوفة من اكسيلوباين أقراص، فاتصل بطبيبك في أقرب وقت ممكن قبل تناول الجرعة التالية.</p><p dir="RTL">قد تحدث الآثار الجانبية التالية إذا تناولت اكسيلوباين أقراص أكثر مما يجب: الشعور بالإعياء، الإسهال، التهاب أو تقرح الأمعاء أو الفم، ألم أو نزيف من الأمعاء أو المعدة، أو كبت&nbsp;النخاع&nbsp;العظمي&nbsp;(انخفاض في نسبة أنواع معينة من خلايا الدم). أخبر طبيبك على الفور إذا كنت تعاني من أي من هذه الأعراض.</p><p dir="RTL"><strong>نسيان تناول أقراص من اكسيلوباين أقراص</strong></p><p dir="RTL">إذا نسيت تناول جرعة اكسيلوباين أقراص فلا تتناول الجرعة الفائتة على الإطلاق. لا تتناول جرعة مضاعفة لتعويض جرعة منسية. بدلاً من ذلك، تابع الجدول الزمني للجرعات بانتظام واستشر طبيبك.</p><p dir="RTL"><strong>التوقف عن تناول أقراص من اكسيلوباين أقراص</strong></p><p dir="RTL">لا توجد أي آثار جانبية ناجمة عن وقف العلاج مع اكسيلوباين أقراص. في حال كنت تستخدم مضادات التخثر من نوع الكومارين (التي تحتوي على سبيل المثال على فينوبروكومون)، إيقاف اكسيلوباين أقراص قد يتطلب أن يقوم الطبيب بتعديل جرعة مضادات التخثر.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL"><strong>توقف</strong> عن تناول اكسيلوباين أقراص على الفور واتصل بطبيبك في حالة حدوث أي من هذه الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الإسهال</strong>: إذا كان لديك زيادة في حركات الأمعاء 4 مرات أو أكثر مقارنة بحالتك الطبيعية لحركات الأمعاء كل يوم أو أي إسهال في الليل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>القيء</strong>: إذا تقيأت أكثر من مرة خلال فترة زمنية مدتها 24 ساعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غثيان</strong>: إذا فقدت شهيتك، وكمية الطعام التي تتناولها كل يوم أقل بكثير من المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب الفم:</strong> إذا كنت تعاني من ألم أو احمرار أو تورم أو تقرحات في فمك و / أو حلقك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>رد فعل الجلد باليد والقدم:</strong> إذا كان لديك ألم أو تورم أو احمرار أو وخز في اليدين و / أو الأقدام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحمى:</strong> إذا كانت درجة حرارة جسمك 38 درجة مئوية أو أكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العدوى:</strong> إذا كنت تعاني من أعراض العدوى التي تسببها البكتيريا أو الفيروسات أو الميكروبات الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ألم في الصدر:</strong> إذا واجهت ألمًا متمركزا في منتصف الصدر، خاصةً إذا حدث أثناء المجهود.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>متلازمة ستيفن جونسون:</strong> إذا كنت تعاني من طفح جلدي مؤلم أحمر أو أرجواني بشكل منتشر وظهور بثور و / أو آفات أخرى تظهر في الغشاء المخاطي (مثل الفم والشفتين)، لا سيما إذا كنت قد تعرضت قبل لحساسية الضوء، والتهابات الجهاز التنفسي (مثل التهاب الشعب الهوائية) و / أو الحمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نقص إنزيم ثنائي هيدرو بيريميدين هيدروجيناز (</strong><strong>DPD</strong><strong>):</strong> إذا كنت تعاني من نقص إنزيم DPD، فأنت معرض بشكل متزايد لخطر السمية المبكرة والتفاعلات الشديدة أو المميتة التي تهدد الحياة والتي تسببها اكسيلوباين أقراص (مثل التهاب الفم والتهاب الغشاء المخاطي والإسهال ونقص&nbsp;الكريات البيضاء المعتدلة)، والسمية العصبية).</p><p dir="RTL">إذا تم اكتشاف هذه الأعراض الجانبية مبكراً، فإنها تتحسن عادةً في غضون يومين إلى ثلاثة أيام بعد توقف العلاج. إذا استمرت هذه الآثار الجانبية، فاتصل بطبيبك على الفور. قد يطلب منك طبيبك استئناف العلاج بجرعة أقل.</p><p dir="RTL">يمكن أن يؤدي رد الفعل التحسسي بجلد اليد والقدم إلى فقدان بصمات الأصابع، مما قد يؤثر على هويتك عن طريق مسح بصمات الأصابع.</p><p dir="RTL">بالإضافة إلى ما سبق، عندما يتم استخدام اكسيلوباين أقراص وحدها، فإن الآثار الجانبية الشائعة جدًا، والتي قد تؤثر على أكثر من شخص من كل 10 أشخاص، هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع بالبطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي أو الجلد الجاف أو الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">هذه الآثار الجانبية يمكن أن تصبح شديدة. لذلك، فمن المهم أن تتصل دائمًا بطبيبك فورًا عندما تبدأ في الشعور بأي آثار جانبية. قد يطلب منك طبيبك تقليل الجرعة و / أو وقف العلاج مؤقتًا باستخدام اكسيلوباين أقراص. سيساعد ذلك في تقليل احتمالية استمرار التأثير الجانبي أو تفاقمه.</p><p dir="RTL"><strong>الآثار الجانبية الأخرى هي:</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى شخص من كل 10 أشخاص) تشمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم البيضاء أو خلايا الدم الحمراء (كما هو موضح في الاختبارات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف، وفقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرق والاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، النعاس، الدوار، احساس غير طبيعي في الجلد (الإحساس بالوخز)، تغيرات بالتذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج العين، زيادة الدموع، احمرار العين (التهاب الملتحمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة (التهاب الوريد الخثاري)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، نزيف الأنف، السعال، سيلان الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القروح الباردة أو التهابات الهربس الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الرئتين أو الجهاز التنفسي (مثل الالتهاب الرئوي أو التهاب الشعب الهوائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الأمعاء، والإمساك، وألم في الجزء العلوي من البطن، وعسر الهضم، والغازات الزائدة، وجفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، تساقط الشعر (الثعلبة)، احمرار بالجلد، الجلد الجاف، الحكة، تلون الجلد، فقدان الجلد، التهاب الجلد، اضطراب الأظافر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل، أو في الأطراف أو الصدر أو الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، وتورم في الأطراف، والشعور بالمرض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في وظائف الكبد (التي تظهر في اختبارات الدم) وزيادة البيليروبين في الدم (يفرزه الكبد)</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى شخص من كل 100 شخص) تشمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الدم، عدوى المسالك البولية، التهاب الجلد، التهابات الأنف والحلق، الالتهابات الفطرية (بما في ذلك تلك الخاصة بالفم)، الأنفلونزا، التهاب المعدة والأمعاء، خراج بالأسنان،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور لكتل تحت الجلد (ورم شحمي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم بما في ذلك الصفائح الدموية، سيولة الدم (كما هو موضح في الاختبارات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السكري، نقص البوتاسيوم في الدم، سوء التغذية، زيادة نسبة الدهون الثلاثية في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة الارتباك، نوبات الهلع، المزاج المكتئب، انخفاض الرغبة الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التحدث وضعف الذاكرة وفقدان التناسق في الحركة واضطراب التوازن والإغماء وتلف الأعصاب (اعتلال الأعصاب) ومشاكل بالإحساس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية المزدوجة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار، ألم الأذن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب والخفقان، ألم في الصدر والنوبات القلبية (احتشاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في الأوردة العميقة، ارتفاع أو انخفاض ضغط الدم، طفح جلدي دافئ، الأطراف الباردة، بقع أرجوانية على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدم في أوردة في الرئة (الانسداد الرئوي)، وفشل رئوي، والسعال الدموي، الربو وضيق في التنفس عند المجهود</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء، وتجمع السوائل في البطن، والتهاب الأمعاء الدقيقة أو الغليظة، المعدة أو المريء، ألم في أسفل البطن، ألم في البطن،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة المعدة (ارتداد الطعام من المعدة)، دم في البراز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرار الجلد والعينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة بالجلد، زيادة في رد فعل الجلد بأشعة الشمس، احمرار راحة اليد، تورم أو ألم الوجه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو تصلب المفاصل، ألم العظام، ضعف العضلات أو تصلبها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع السوائل في الكلى، زيادة معدلات التبول أثناء الليل، سلس البول، دم في البول، زيادة نسبة الكرياتينين في الدم (علامة على اختلال وظائف الكلى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف غير عادي من المهبل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (وذمة)، قشعريرة وتيبس</p><p dir="RTL">بعض هذه الآثار الجانبية أكثر شيوعًا تحدث عندما يتم استخدام اكسيلوباين أقراص مع أدوية أخرى لعلاج السرطان. الآثار الجانبية الأخرى التي تظهر في هذه الحالات هي:</p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى شخص من كل 10 أشخاص) تشمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في صوديوم الدم والماغنيسيوم أو الكالسيوم، وزيادة في نسبة السكر في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الأعصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرنين أو الطنين في الأذنين (طنين الأذن)، وفقدان السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الزغطة، والتغيير في الصوت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو الشعور ب إحساس متغير / غير طبيعي في الفم، ألم في الفك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق والتعرق الليلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التبول أو ظهور الدم أو البروتين في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات أو رد فعل تحسسي في موقع الحقن (الناجم عن الأدوية التي تعطى عن طريق الحقن في نفس الوقت)</p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى شخص من كل 1000 شخص) تشمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضييق أو انسداد القناة المسيلة للدموع (تضيق القناة الدمعية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تليف كبدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب يؤدي إلى خلل وظيفي أو انسداد في إفراز الصفراء (التهاب الكبد الصفراوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات محددة في تخطيط القلب الكهربائي (إطالة فترة QT)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أنواع معينة من عدم انتظام ضربات القلب (بما في ذلك الرجفان البطيني، تسرُّع القلب&nbsp;البطيني، وبطء القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين الذي يسبب ألم العين وربما مشاكل في البصر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد الذي يسبب بقع حمراء متقشرة بسبب مرض الجهاز المناعي</p><p dir="RTL"><strong>تشمل الآثار الجانبية النادرة جدًا (التي قد تؤثر على ما يصل إلى شخص من كل 10000 شخص) ما يلي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل شديد للجلد مثل الطفح الجلدي، تقرح الجلد أو ظهور تقرحات قد تشمل تقرحات في الفم والأنف والأعضاء التناسلية واليدين والقدمين والعينين (عيون حمراء ومنتفخة)</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء عند درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء في العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم اكسيلوباين أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما تحتويه اكسيلوباين أقراص</strong></p><p dir="RTL">المادة الفعالة هي كابيسيتابين.</p><p dir="RTL"><strong>اكسيلوباين أقراص 150 ملغم أقراص المتوافق مع دستور الأدوية الأمريكي</strong></p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 150 ملغم كابيسيتابين المتوافق مع دستور الأدوية الأمريكي.</p><p dir="RTL"><strong>اكسيلوباين أقراص 500 ملغم أقراص المتوافق مع دستور الأدوية الأمريكي</strong></p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 500 ملغم كابيسيتابين المتوافق مع دستور الأدوية الأمريكي.</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: هيبروميلوز 2910 5cps (ميثوسيل بريميوم E5 LV) السليلوز دقيق التبلور (أفيسيل PH 112)، اللاكتوز اللامائي (Super tab 21 AN)، كروس كارميلوز صوديوم (Ac-Di-Sol)، ستيارات الماغنيسيوم، المياه النقية.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: هيبروميلوز/ HPMC 2910، ثاني أكسيد التيتانيوم، أكسيد الحديد الأحمر، أكسيد الحديد الأصفر، تلك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو شكل اكسيلوباين أقراص ومحتويات العلبة؟</strong></p><p dir="RTL"><strong>اكسيلوباين أقراص 150 ملغم أقراص</strong></p><p dir="RTL">أقراص على شكل كبسولات، ذات لون الخوخ الفاتح محدبة الوجهين والأقراص مغلفة بطبقة رقيقة ومدموغة برقم &quot;6&quot; من جانب و &quot;H&quot; على الجانب الآخر.</p><p dir="RTL"><strong>اكسيلوباين أقراص 500 ملغم أقراص</strong></p><p dir="RTL">أقراص على شكل كبسولات، ذات لون الخوخ الفاتح محدبة الوجهين والأقراص مغلفة بطبقة رقيقة ومدموغة برقم &quot;3&quot; من جانب و &quot;H&quot; على الجانب الآخر.</p><p dir="RTL"><strong>توافر اكسيلوباين أقراص:</strong></p><p dir="RTL">يتوافر اكسيلوباين أقراص في عبوات حاوية.</p><p dir="RTL">تحتوي عبوة اكسيلوباين أقراص 150 ملغم أقراص على 60 قرص عبارة عن ستة شرائط بكل منها 10 أقراص</p><p dir="RTL">تحتوي عبوة اكسيلوباين أقراص 500 ملغم أقراص على 60 قرص عبارة عن ستة شرائط بكل منها 10 أقراص</p><p dir="RTL">قد لا يتم تسويق كافة أحجام العبوات</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية.</p><p dir="RTL">تليفون: &nbsp;+ 966 114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             يونيو/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capecitabine Tablets USP 500mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets USP 500mg : 
Each film coated tablet contains 500 mg of Capecitabine USP 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capecitabine Tablets USP 500mg 
Peach -colored, oval shaped, biconvex, film -coated tablets debossed with '3' on one side and 'H' on the other side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine Tablets is indicated for the treatment of:</p><p>-&nbsp; for the adjuvant treatment of patients following surgery of stage III (Dukes&#39; stage C) colon cancer.</p><p>-&nbsp; Metastatic colorectal cancer.</p><p>-&nbsp; first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. <strong>&nbsp;</strong>- in combination with docetaxel for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.&nbsp;</p><p>-&nbsp; as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine Tablets should only be prescribed by a qualified physician experienced in the utilisation of anti-neoplastic medicinal products. Careful monitoring during the first cycle of treatment is recommended for all patients.&nbsp;</p><p>Treatment should be discontinued if progressive disease or intolerable toxicity is observed. Standard and reduced dose calculations according to body surface area for starting doses of Capecitabine Tablets of 1250 mg/m<sup>2</sup> and 1000 mg/m<sup>2</sup> are provided in tables 1 and 2, respectively.</p><p>Posology&nbsp;</p><p>Recommended posology (see section 5.1):</p><p><em><u>Monotherapy</u></em>&nbsp;</p><p>Colon, colorectal and breast cancer &nbsp;</p><p>Given as monotherapy, the recommended starting dose for capecitabine in the adjuvant treatment of colon cancer, in the treatment of metastatic colorectal cancer or of locally advanced or metastatic breast cancer is 1250 mg/m<sup>2</sup> administered twice daily (morning and evening; equivalent to 2500 mg/m<sup>2</sup> total daily dose) for 14 days followed by a 7-day rest period. Adjuvant treatment in patients with stage III colon cancer is recommended for a total of 6 months</p><p><em><u>Combination therapy</u></em>&nbsp;</p><p>Colon, colorectal and gastric cancer&nbsp;</p><p>In combination treatment, the recommended starting dose of capecitabine should be reduced to 800 - 1000 mg/m<sup>2</sup> when administered twice daily for 14 days followed by a 7-day rest period, or to 625 mg/m<sup>2</sup> twice daily when administered continuously (see section 5.1). For combination with Irinotecan, the recommended starting dose is 800 mg/m<sup>2</sup> when administered twice daily for 14 days followed by a 7-day rest period combined with Irinotecan 200 mg/m<sup>2</sup> on day 1. The inclusion of bevacizumab in a combination regimen has no effect on the starting dose of capecitabine. Premedication to maintain adequate hydration and anti-emesis according to the cisplatin summary of product characteristics should be started prior to cisplatin administration for patients receiving the capecitabine plus cisplatin combination. Premedication with antiemetics according to the oxaliplatin summary of product characteristics is recommended for patients receiving the capecitabine plus oxaliplatin combination. Adjuvant treatment in patients with stage III colon cancer is recommended for a duration of 6 months.&nbsp;</p><p>Breast cancer&nbsp;</p><p>In combination with docetaxel, the recommended starting dose of capecitabine in the treatment of metastatic breast cancer is 1250 mg/m<sup>2</sup> twice daily for 14 days followed by a 7- day rest period, combined with docetaxel at 75 mg/m<sup>2</sup> as a 1 hour intravenous infusion every 3 weeks. Premedication with an oral corticosteroid such as dexamethasone according to the docetaxel summary of product characteristics should be started prior to docetaxel administration for patients receiving the capecitabine plus docetaxel combination.</p><p>Capecitabine Tablets dose calculations&nbsp;</p><p>Table 1 Standard and reduced dose calculations according to body surface area for a starting dose of capecitabine of 1250 mg/m<sup>2</sup>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Dose level 1250 mg/m<sup>2</sup> (twice daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Full dose</p><p>1250 mg/m<sup>2</sup></p></td><td colspan="2" style="vertical-align:top"><p>Number of 150 mg tablets and/or 500 mg tablets per</p><p>administration (each administration to be given morning and</p></td><td style="vertical-align:top"><p>Reduced dose</p><p>(75%)</p><p>950 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>Reduced dose</p><p>(50%)</p><p>625 mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>evening)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Body Surface</p><p>Area (m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose per administration</p><p>(mg)</p></td><td><p>150 mg</p></td><td><p>500 mg</p></td><td style="vertical-align:top"><p>Dose per administration (mg)</p></td><td style="vertical-align:top"><p>Dose per administration (mg)</p></td></tr><tr><td style="vertical-align:top"><p>&le;1.26</p></td><td style="vertical-align:top"><p>1500</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1150</p></td><td style="vertical-align:top"><p>800</p></td></tr><tr><td style="vertical-align:top"><p>1.27 - 1.38</p></td><td style="vertical-align:top"><p>1650</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1300</p></td><td style="vertical-align:top"><p>800</p></td></tr><tr><td style="vertical-align:top"><p>1.39 - 1.52</p></td><td style="vertical-align:top"><p>1800</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1450</p></td><td style="vertical-align:top"><p>950</p></td></tr><tr><td style="vertical-align:top"><p>1.53 - 1.66</p></td><td style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1500</p></td><td style="vertical-align:top"><p>1000</p></td></tr><tr><td style="vertical-align:top"><p>1.67 - 1.78</p></td><td style="vertical-align:top"><p>2150</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1650</p></td><td style="vertical-align:top"><p>1000</p></td></tr><tr><td style="vertical-align:top"><p>1.79 - 1.92</p></td><td style="vertical-align:top"><p>2300</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1800</p></td><td style="vertical-align:top"><p>1150</p></td></tr><tr><td style="vertical-align:top"><p>1.93 - 2.06</p></td><td style="vertical-align:top"><p>2500</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1950</p></td><td style="vertical-align:top"><p>1300</p></td></tr><tr><td style="vertical-align:top"><p>2.07 - 2.18</p></td><td style="vertical-align:top"><p>2650</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>1300</p></td></tr><tr><td style="vertical-align:top"><p>&ge;2.19</p></td><td style="vertical-align:top"><p>2800</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>2150</p></td><td style="vertical-align:top"><p>1450</p></td></tr></tbody></table><p>Table 2 Standard and reduced dose calculations according to body surface area for a starting dose of capecitabine of 1000 mg/m<sup>2 </sup></p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Dose level 1000 mg/m<sup>2</sup> (twice daily)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Full dose</p><p>1000 mg/m<sup>2</sup></p></td><td colspan="2" style="vertical-align:top"><p>Number of 150 mg tablets and/or 500 mg tablets per</p><p>administration (each administration to be</p><p>given morning and evening)</p></td><td style="vertical-align:top"><p>Reduced dose</p><p>(75%)</p><p>750 mg/m<sup>2</sup></p></td><td style="vertical-align:top"><p>Reduced dose</p><p>(50%)</p><p>500 mg/m<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Body Surface</p><p>Area (m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose per administration</p><p>(mg)</p></td><td><p>150 mg</p></td><td><p>500 mg</p></td><td style="vertical-align:top"><p>Dose per administration (mg)</p></td><td style="vertical-align:top"><p>Dose per administration (mg)</p></td></tr><tr><td style="vertical-align:top"><p>&le;1.26</p></td><td style="vertical-align:top"><p>1150</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>800</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>1.27 - 1.38</p></td><td style="vertical-align:top"><p>1300</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1000</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>1.39 - 1.52</p></td><td style="vertical-align:top"><p>1450</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1100</p></td><td style="vertical-align:top"><p>750</p></td></tr><tr><td style="vertical-align:top"><p>1.53 - 1.66</p></td><td style="vertical-align:top"><p>1600</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1200</p></td><td style="vertical-align:top"><p>800</p></td></tr><tr><td style="vertical-align:top"><p>1.67 - 1.78</p></td><td style="vertical-align:top"><p>1750</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1300</p></td><td style="vertical-align:top"><p>800</p></td></tr><tr><td style="vertical-align:top"><p>1.79 - 1.92</p></td><td style="vertical-align:top"><p>1800</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1400</p></td><td style="vertical-align:top"><p>900</p></td></tr><tr><td style="vertical-align:top"><p>1.93 - 2.06</p></td><td style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1500</p></td><td style="vertical-align:top"><p>1000</p></td></tr><tr><td style="vertical-align:top"><p>2.07 - 2.18</p></td><td style="vertical-align:top"><p>2150</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1600</p></td><td style="vertical-align:top"><p>1050</p></td></tr><tr><td style="vertical-align:top"><p>&ge;2.19</p></td><td style="vertical-align:top"><p>2300</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1750</p></td><td style="vertical-align:top"><p>1100</p></td></tr></tbody></table><p><em><u>Posology adjustments during treatment</u></em>&nbsp;</p><p>General&nbsp;</p><p>Toxicity due to capecitabine administration may be managed by symptomatic treatment and/or modification of the dose (treatment interruption or dose reduction). Once the dose has been reduced, it should not be increased at a later time. For those toxicities considered by the treating physician to be unlikely to become serious or life-threatening, e.g. alopecia, altered taste, nail changes, treatment can be continued at the same dose without reduction or interruption. Patients taking capecitabine should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs. Doses of capecitabine omitted for toxicity are not replaced.</p><p>The following are the recommended dose modifications for toxicity:&nbsp;</p><p>Table 3 Capecitabine dose reduction shedule (3 weekly cycle or continuous treatment)</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity grades*</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose changes within a treatment cycle</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose &nbsp;&nbsp;&nbsp;&nbsp; adjustment &nbsp;&nbsp;&nbsp; for </strong></p><p><strong>cycle/dose</strong>&nbsp;</p><p><strong>(% of starting dose)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>next </strong></p></td></tr><tr><td style="vertical-align:top"><p>&bull; <em>Grade 1</em></p></td><td style="vertical-align:top"><p>Maintain dose level</p></td><td style="vertical-align:top"><p>Maintain dose level</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; <em>Grade 2</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-1st appearance</p></td><td rowspan="3" style="vertical-align:top"><p>Interrupt until resolved to grade 0-1</p></td><td colspan="2" style="vertical-align:top"><p>100%</p></td></tr><tr><td style="vertical-align:top"><p>-2nd appearance</p></td><td colspan="2" style="vertical-align:top"><p>75%</p></td></tr><tr><td style="vertical-align:top"><p>-3rd appearance</p></td><td colspan="2" style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-4th appearance</p></td><td style="vertical-align:top"><p>Discontinue treatment permanently</p></td><td colspan="2" style="vertical-align:top"><p>Not applicable</p></td></tr><tr><td style="vertical-align:top"><p>&bull; <em>Grade 3</em></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-1st appearance</p></td><td rowspan="2" style="vertical-align:top"><p>Interrupt until resolved to grade 0-1</p></td><td colspan="2" style="vertical-align:top"><p>75%</p></td></tr><tr><td style="vertical-align:top"><p>-2nd appearance</p></td><td colspan="2" style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-3rd appearance</p></td><td style="vertical-align:top"><p>Discontinue treatment permanently</p></td><td colspan="2" style="vertical-align:top"><p>Not applicable</p></td></tr><tr><td style="vertical-align:top"><p>&bull; <em>Grade 4</em></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-1st appearance</p></td><td style="vertical-align:top"><p>Discontinue permanently&nbsp; <em>or</em>&nbsp;</p><p>If physician deems it to be in the patient&#39;s best interest to continue, interrupt until resolved to grade 0-1</p></td><td colspan="2" style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-2nd appearance</p></td><td style="vertical-align:top"><p>Discontinue permanently</p></td><td colspan="2" style="vertical-align:top"><p>Not applicable</p></td></tr></tbody></table><p>*According to the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) Common Toxicity Criteria (version 1) or the Common Terminology Criteria for Adverse Events (CTCAE) of the Cancer Therapy Evaluation Program, US National Cancer Institute, version 4.0.</p><p>For hand-foot syndrome and hyperbilirubinemia, see section 4.4.</p><p>Haematology&nbsp;</p><p>Patients with baseline neutrophil counts of &lt;1.5 x 10<sup>9</sup>/L and/or thrombocyte counts of &lt;100 x 10<sup>9</sup>/L should not be treated with capecitabine. If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below 1.0 x 10<sup>9</sup>/L or that the platelet count drops below 75 x 10<sup>9</sup>/L, treatment with capecitabine should be interrupted.&nbsp;</p><p>Dose modifications for toxicity when capecitabine is used as a 3 weekly cycle in combination with other medicinal products&nbsp;</p><p>Dose modifications for toxicity when capecitabine is used as a 3 weekly cycle in combination with other medicinal products should be made according to table 3 above for capecitabine and according to the appropriate summary of product characteristics for the other medicinal product(s).&nbsp;</p><p>At the beginning of a treatment cycle, if a treatment delay is indicated for either capecitabine or the other medicinal product(s), then administration of all therapy should be delayed until the requirements for restarting all medicinal products are met.&nbsp;</p><p>During a treatment cycle for those toxicities considered by the treating physician not to be related to capecitabine, capecitabine should be continued and the dose of the other medicinal product should be adjusted according to the appropriate Prescribing Information.</p><p>If the other medicinal product(s) have to be discontinued permanently, capecitabine treatment can be resumed when the requirements for restarting capecitabine are met.&nbsp;</p><p>This advice is applicable to all indications and to all special populations.</p><p>Dose modifications for toxicity when capecitabine is used continuously in combination with other medicinal products&nbsp;</p><p>Dose modifications for toxicity when capecitabine is used continuously in combination with other medicinal products should be made according to table 3 above for capecitabine and according to the appropriate summary of product characteristics for the other medicinal product(s).</p><p><em><u>Posology adjustments for special populations:</u></em>&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>Insufficient safety and efficacy data are available in patients with hepatic impairment to provide a dose adjustment recommendation. No information is available on hepatic impairment due to cirrhosis or hepatitis.&nbsp;</p><p>Renal impairment&nbsp;</p><p>Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min [Cockcroft and Gault] at baseline). The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min at baseline) is increased compared to the overall population. In patients with moderate renal impairment at baseline, a dose reduction to 75% for a starting dose of 1250 mg/m<sup>2</sup> is recommended. In patients with moderate renal impairment at baseline, no dose reduction is required for a starting dose of 1000 mg/m<sup>2</sup>. In patients with mild renal impairment (creatinine clearance 51-80 ml/min at baseline) no adjustment of the starting dose is recommended. Careful monitoring and prompt treatment interruption is recommended if the patient develops a grade 2, 3 or 4 adverse events during treatment and subsequent dose adjustment as outlined in table 3 above. If the calculated creatinine clearance decreases during treatment to a value below 30 ml/min, Capecitabine Tablets should be discontinued. These dose adjustment recommendations for renal impairment apply both to monotherapy and combination use (see also section &ldquo;Elderly&rdquo; below).</p><p>Elderly&nbsp;</p><p>During capecitabine monotherapy, no adjustment of the starting dose is needed. However, grade 3 or 4 treatment-related adverse reactions were more frequent in patient&rsquo;s &ge;60 years of age compared to younger patients.</p><p>When capecitabine was used in combination with other medicinal products, elderly patients (&ge;65 years) experienced more grade 3 and grade 4 adverse drug reactions, including those leading to discontinuation, compared to younger patients. Careful monitoring of patients &ge;60 years of age is advisable.&nbsp;</p><p>- <em>In combination with docetaxel</em>: an increased incidence of grade 3 or 4 treatment-related adverse reactions and treatment-related serious adverse reactions were observed in patients 60 years of age or more (see section 5.1). For patients 60 years of age or more, a starting dose reduction of capecitabine to 75% (950 mg/m<sup>2</sup> twice daily) is recommended. If no toxicity is observed in patients &ge;60 years of age treated with a reduced capecitabine starting dose in combination with docetaxel, the dose of capecitabine may be cautiously escalated to 1250 mg/m<sup>2</sup> twice daily.&nbsp;</p><p>Paediatric population&nbsp;</p><p>There is no relevant use of capecitabine in the Paediatric population in the indications colon, colorectal, gastric and breast cancer.</p><p>Method of administration&nbsp;</p><p>Capecitabine Tablets should be swallowed with water within 30 minutes after a meal.</p><p>Capecitabine Tablets should not be Crushed or cut.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                History of severe and unexpected reactions to fluoropyrimidine therapy,  
•	Hypersensitivity to capecitabine or to any of the excipients listed in section 6.1 or fluorouracil, 
•	In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity 
(see section 4.4),  
•	During pregnancy and lactation, 
•	In patients with severe leukopenia, neutropenia, or thrombocytopenia,  
•	In patients with severe hepatic impairment,  
•	In patients with severe renal impairment (creatinine clearance below 30 ml/min), 
•	Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug-drug 
interaction), 
•	If contraindications exist to any of the medicinal products in the combination regimen, that medicinal product should not be used. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dose limiting toxicities&nbsp;</p><p><u>Dose limiting toxicities </u>include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia). Most adverse reactions are reversible and do not require permanent discontinuation of therapy, although doses may need to be withheld or reduced.&nbsp;</p><p><em><u>Diarrhoea</u></em><u>.</u> Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated. Standard anti diarrhoeal treatments (e.g. loperamide) may be used. NCIC CTC grade 2 diarrhoea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhoea as an increase of 7 to 9 stools/day or incontinence and malabsorption. Grade 4 diarrhoea is an increase of &ge;10 stools/day or grossly bloody diarrhoea or the need for parenteral support. Dose reduction should be applied as necessary (see section 4.2).</p><p><em><u>Dehydration</u>.</em> Dehydration should be prevented or corrected at the onset. Patients with anorexia, asthenia, nausea, vomiting or diarrhoea may rapidly become dehydrated. Dehydration may cause acute renal failure, especially in patients with pre-existing compromised renal function or when capecitabine is given concomitantly with known nephrotoxicmedicinal products. Acute renal failure secondary to dehydration might be potentially fatal. If grade 2 (or higher) dehydration occurs, capecitabine treatment should be immediately interrupted and the dehydration corrected. Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled. Dose modifications applied should be applied for the precipitating adverse event as necessary (see section 4.2).</p><p><em><u>Hand-foot syndrome</u> </em>(also known as hand-foot skin reaction or palmar-plantar erythrodysesthesia or chemotherapy induced acral erythema). Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient&#39;s normal activities</p><p>Grade 2 hand-foot syndrome is painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient&#39;s activities of daily living.Grade 3 hand-foot syndrome is moist desquamation, ulceration, blistering and severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living. Persistent or severe hand-foot syndrome (Grade 2 and above) can eventually lead to loss of fingerprints which could impact patient identification. If grade 2 or 3 hand-foot syndrome occurs, administration of capecitabine should be interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-foot syndrome, subsequent doses of capecitabine should be decreased. When capecitabine and cisplatin are used in combination, the use of vitamin B6 (pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand&ndash;foot syndrome, because of published reports that it may decrease the efficacy of cisplatin. There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Capecitabine Tablets</p><p><em><u>Cardiotoxicity.</u></em> Cardiotoxicity has been associated with fluoropyrimidine therapy, including myocardial infarction, angina, dysrhythmias, cardiogenic shock, sudden death and electrocardiographic changes (including very rare cases of QT prolongation). These adverse reactions may be more common in patients with a prior history of coronary artery disease. Cardiac arrhythmias (including ventricular fibrillation, torsade de pointes, and bradycardia), angina pectoris, myocardial infarction, heart failure and cardiomyopathy have been reported in patients receiving capecitabine. Caution must be exercised in patients with history of significant cardiac disease, arrhythmias and angina pectoris (see section 4.8).&nbsp;</p><p><em><u>Hypo- or hypercalcaemia</u>.</em> Hypo- or hypercalcaemia has been reported during capecitabine treatment. Caution must be exercised in patients with pre-existing hypo- or hypercalcaemia (see section 4.8).&nbsp;</p><p><em><u>Central or peripheral nervous system disease</u>.</em> Caution must be exercised in patients with central or peripheral nervous system disease, e.g. brain metastasis or neuropathy (see section 4.8).&nbsp;</p><p><em><u>Diabetes mellitus or electrolyte disturbances</u>.</em> Caution must be exercised in patients with diabetes mellitus or electrolyte disturbances, as these may be aggravated during capecitabine treatment</p><p><em><u>Coumarin-derivative anticoagulation</u>.</em> In an interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC (+57%) of S-warfarin. These results suggest an interaction, probably due to an inhibition of the cytochrome P450 2C9 isoenzyme system by capecitabine. Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely and the anticoagulant dose adjusted accordingly (see section 4.5).</p><p><em><u>Brivudine.</u></em> Brivudine must not be administered concomitantly with capecitabine. Fatal cases have been reported following this drug interaction. There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy. Treatment with brivudine can be started 24 hours after the last dose of capecitabine (see section 4.3 and 4.5). In the event of accidental administration of brivudine to patients being treated with capecitabine, effective measures should be taken to reduce the toxicity of capecitabine. Immediate admission to hospital is recommended. All measures should be initiated to prevent systemic infections and dehydration.</p><p><em><u>Hepatic impairment</u>.</em> In the absence of safety and efficacy data in patients with hepatic impairment, Capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis. Administration of capecitabine should be interrupted if treatment-related elevations in bilirubin of &gt;3.0 x ULN or treatment-related elevations in hepatic aminotransferases (ALT, AST) of &gt;2.5 x ULN occur.</p><p>Treatment with capecitabine monotherapy may be resumed when bilirubin decreases to &le;3.0 x ULN or hepatic aminotransferases decrease to &le; 2.5 x ULN.&nbsp;</p><p><em><u>Renal impairment</u>.</em> The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50 ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).&nbsp;</p><p><em><u>Dihydropyrimidine dehydrogenase (DPD) deficiency</u></em>: Rarely, unexpected, severe toxicity (e.g. stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity) associated with 5-</p><p>FU has been attributed to a deficiency of DPD activity</p><p>Patients with low or absent DPD activity, an enzyme involved in fluorouracil degradation, are at increased risk for severe, life-threatening, or fatal adverse reactions caused by fluorouracil. Although DPD deficiency cannot be precisely defined, it is known that patients with certain homozygous or certain compound heterozygous mutations in the <em>DPYD</em> gene locus (e.g. DPYD*2A, c.1679T&gt;G, c.2846A&gt;T and c.1236G&gt;A/HapB3 variants), which can cause complete or near complete absence of DPD enzymatic activity (as determined from laboratory assays), have the highest risk of life-threatening or fatal toxicity and should not be treated with Capecitabine Tablets (see section 4.3). No dose has been proven safe for patients with complete absence of DPD activity.</p><p>Patients with certain heterozygous DPYD variants (including DPYD*2A, c.1679T&gt;G, c.2846A&gt;T and c.1236G&gt;A/HapB3 variants) have been shown to have increased risk of severe toxicity when treated with capecitabine.&nbsp;</p><p>The frequency of the heterozygous DPYD*2A genotype in the DPYD gene in Caucasian patients is around 1%, 1.1% for c.2846A&gt;T, 2.6-6.3% for c.1236G&gt;A/HapB3 variants and 0.07 to 0.1% for c.1679T&gt;G. Genotyping for these alleles is recommended to identify patients at increased risk for severe toxicity. Data on the frequency of these DPYD variants in other populations than Caucasian is limited. It cannot be excluded that other rare variants may also be associated with an increased risk of severe toxicity.</p><p>For patients with partial DPD deficiency (such as those with heterozygous mutations in the <em>DPYD</em> gene) and where the benefits of Capecitabine Tablets are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution and frequent monitoring with dose adjustment according to toxicity. A reduction of the starting dose in these patients may be considered to avoid serious toxicity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by specific test. It has been reported that the DPYD*2A, c.1679T&gt;G variants lead to a greater reduction in enzymatic activity than the other variants with a higher risk of side effects. The consequences of a reduced dose for efficacy are currently uncertain. Therefore, in the absence of serious toxicity the dose could be increased while carefully monitoring the patient</p><p>&nbsp;The patients who are tested negative for the above-mentioned alleles may still have a risk of severe adverse events.</p><p>In patients with unrecognized DPD deficiency treated with capecitabine as well as in those patients who test negative for specific <em>DPYD</em> variations, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9). In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately. Permanent discontinuation should be considered based on clinical assessment of the onset, duration and severity of the observed toxicities.&nbsp;</p><p><em><u>Ophthalmologic complications:</u></em> Patients should be carefully monitored for ophthalmological complications such as keratitis and corneal disorders, especially if they have a prior history of eye disorders. Treatment of eye disorders should be initiated as clinically appropriate.</p><p><em><u>Severe skin reactions:</u></em> Capecitabine Tablets can induce severe skin reactions such as StevensJohnson syndrome and Toxic Epidermal Necrolysis. Capecitabine Tablets should be permanently discontinued in patients who experience a severe skin reaction during treatment.</p><p>As this medicinal product contains anhydrous lactose as an excipient, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Capecitabine tablets should not be crushed or cut. In case of exposure of either patient or caregiver to crushed or cut Capecitabine tablets adverse drug reactions could occur. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>Interaction with other medicinal products&nbsp;</p><p><em><u>Brivudine:</u></em> a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-Fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described. This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal. Therefore, brivudine must not be administered concomitantly with capecitabine (see section 4.3 and 4.4). There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy.</p><p>Treatment with brivudine can be started 24 hours after the last dose of capecitabine.</p><p><em><u>Cytochrome P-450 2C9 substrates:</u> </em>Other than warfarin, no formal interaction studies between capecitabine and other CYP2C9 substrates have been conducted. Care should be exercised when capecitabine is co-administered with 2C9 substrates (e.g., phenytoin). See also interaction with coumarin-derivative anticoagulants below, and section 4.4.</p><p><em><u>Coumarin-derivative anticoagulants:</u></em> altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. These reactions occurred within several days and up to several months after initiating capecitabine therapy and, in a few cases, within one month after stopping capecitabine. In a clinical pharmacokinetic interaction study, after a single 20 mg dose of warfarin, capecitabine treatment increased the AUC of S-warfarin by 57% with a 91% increase in INR value. Since metabolism of R-warfarin was not affected, these results indicate that capecitabine down-regulates isozyme 2C9, but has no effect on isozymes 1A2 and 3A4. Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anticoagulant dose adjusted accordingly.</p><p><em><u>Phenytoin:</u></em> increased phenytoin plasma concentrations resulting in symptoms of phenytoin intoxication in single cases have been reported during concomitant use of capecitabine with phenytoin. Patients taking phenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.&nbsp;</p><p><em><u>Folinic acid/folic acid</u></em><u>:</u> a combination study with capecitabine and folinic acid indicated that folinic acid has no major effect on the pharmacokinetics of capecitabine and its metabolites. However, folinic acid has an effect on the pharmacodynamics of capecitabine and its toxicity may be enhanced by folinic acid: the maximum tolerated dose (MTD) of capecitabine alone using the intermittent regimen is 3000 mg/m<sup>2</sup> per day whereas it is only 2000 mg/m<sup>2</sup> per day when capecitabine was combined with folinic acid (30 mg orally bid). The enhanced toxicity may be relevant when switching from 5- FU/LV to a capecitabine regimen. This may also be relevant with folic acid supplementation for folate deficiency due to the similarity between folinic acid and folic acid.</p><p><em><u>Antacid:</u></em> the effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the pharmacokinetics of capecitabine was investigated. There was a small increase in plasma concentrations of capecitabine and one metabolite (5&#39;-DFCR); there was no effect on the 3 major metabolites (5&#39;-DFUR, 5-FU and FBAL).&nbsp;</p><p><em><u>Allopurinol:</u> </em>interactions with allopurinol have been observed for 5-FU; with possible decreased efficacy of 5-FU. Concomitant use of allopurinol with capecitabine should be avoided.</p><p><em><u>Interferon alpha:</u> </em>the MTD of capecitabine was 2000 mg/m<sup>2</sup> per day when combined with interferon alpha-2a (3 MIU/m<sup>2</sup> per day) compared to 3000 mg/m<sup>2</sup> per day when capecitabine was used alone.</p><p><em><u>Radiotherapy:</u></em> the MTD of capecitabine alone using the intermittent regimen is 3000 mg/m<sup>2</sup> per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of capecitabine is 2000 mg/m<sup>2</sup> per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy.&nbsp;</p><p><em><u>Oxaliplatin</u></em><u>:</u> no clinically significant differences in exposure to capecitabine or its metabolites, free platinum or total platinum occurred when capecitabine was administered in combination with oxaliplatin or in combination with oxaliplatin and bevacizumab.</p><p><em><u>Bevacizumab</u></em><u>: </u>there was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of capecitabine or its metabolites in the presence of oxaliplatin.</p><p>Food interaction &nbsp;</p><p>In all clinical trials, patients were instructed to administer capecitabine within 30 minutes after a meal. Since current safety and efficacy data are based upon administration with food, it is recommended that capecitabine be administered with food. Administration with food decreases the rate of capecitabine absorption (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females&nbsp;</u></p><p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with capecitabine. If the patient becomes pregnant while receiving capecitabine, the potential hazard to the foetus must be explained. An effective method of contraception should be used during treatment and 6months after the last dose of Capecitabine.</p><p>Based on genetic toxicity findings, male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months following the last dose of capecitabine</p><p><u>Pregnancy&nbsp;</u></p><p>There are no studies in pregnant women using capecitabine; however, it should be assumed that capecitabine may cause foetal harm if administered to pregnant women. In reproductive toxicity studies in animals, capecitabine administration caused embryolethality and teratogenicity. These findings are expected effects of fluoropyrimidine derivatives. Capecitabine is contraindicated during pregnancy.&nbsp;</p><p><u>Breast-feeding&nbsp;</u></p><p>It is not known whether capecitabine is excreted in human breast milk. No studies have been conducted to assess the impact of capecitabine on milk production or its presence in human breast milk In lactating mice, considerable amounts of capecitabine and its metabolites were found in milk. As the potential for harm to the nursing infant is unknown Breast-feeding should be discontinued while receiving treatment with capecitabine and for 2 weeks after the final dose.</p><p><u>Fertility&nbsp;</u></p><p>There is no data on Capecitabine Tablets and impact on fertility. The Capecitabine Tablets pivotal studies included females of childbearing potential and males only if they agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a reasonable period thereafter.&nbsp;</p><p>In animal studies effects on fertility were observed (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine has minor or moderate influence on the ability to drive and use machines.</p><p>Capecitabine may cause dizziness, fatigue and nausea.<strong>&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile&nbsp;</p><p>The overall safety profile of capecitabine is based on data from over 3000 patients treated with capecitabine as monotherapy or capecitabine in combination with different chemotherapy regimens in multiple indications. The safety profiles of capecitabine monotherapy for the metastatic breast cancer, metastatic colorectal cancer and adjuvant colon cancer populations are comparable. See section 5.1 for details of major studies, including study designs and major efficacy results.</p><p>The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal pain, stomatitis), hand-foot syndrome (palmar-plantar erythrodysesthesia), fatigue, asthenia, anorexia,<em> </em>cardiotoxicity, increased renal dysfunction on those with preexisting compromised renal function, and thrombosis/embolism.&nbsp;</p><p>Tabulated list of adverse reactions&nbsp;</p><p>ADRs considered by the investigator to be possibly, probably, or remotely related to the administration of capecitabine are listed in table 4 for capecitabine given as monotherapy and in table 5 for capecitabine given in combination with different chemotherapy regimens in multiple indications. The following headings are used to rank the ADRs by frequency: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000). Within each frequency grouping, ADRs are presented in order of decreasing seriousness.</p><p><em><u>Capecitabine Monotherapy:</u> </em>&nbsp;</p><p>Table 4 lists ADRs associated with the use of capecitabine monotherapy based on a pooled analysis of safety data from three major studies including over 1900 patients (studies M66001, SO14695, and SO14796). ADRs are added to the appropriate frequency grouping according to the overall incidence from the pooled analysis.&nbsp;</p><p>Table 4 Summary of related ADRs reported in patients treated with capecitabine monotherapy&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Body System </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very Common</strong>&nbsp;</p><p><strong><em>All grades</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong>&nbsp;</p><p><strong><em>All grades</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong>&nbsp;</p><p><strong><em>Severe &nbsp;&nbsp;&nbsp; and/or &nbsp;&nbsp;&nbsp;&nbsp; Life-</em></strong></p><p><strong><em>threatening (grade 3-4) or considered medically relevant</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Rare/Very Rare</strong>&nbsp;</p><p><strong>(Post-Marketing </strong></p><p><strong>Experience)</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Infections &nbsp;&nbsp;&nbsp; and </em></p><p><em>infestations</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Herpes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral</p><p>infection,</p><p>Nasopharyngitis, Lower respiratory</p><p>tract infection&nbsp;</p></td><td style="vertical-align:top"><p>Sepsis, Urinary tract infection, Cellulitis, Tonsillitis, Pharyngitis,</p><p>Oral &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; candidiasis,</p><p>Influenza,</p><p>Gastroenteritis, Fungal infection, Infection,</p><p>Tooth abscess</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Neoplasm benign, malignant &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and </em></p><p><em>unspecified</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Lipoma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood &nbsp; and lymphatic system disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Neutropenia,</p><p>Anaemia</p></td><td style="vertical-align:top"><p>Febrile &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neutropenia,</p><p>Pancytopenia,</p><p>Granulocytopenia,</p><p>Thrombocytopenia,</p><p>Leukopenia, Haemolytic</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>anaemia, International Normalised Ratio (INR) increased/Prothrombin time prolonged</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Dehydration,</p><p>Weight decreased</p></td><td colspan="2" style="vertical-align:top"><p>Diabetes,</p><p>Hypokalaemia, Appetite disorder, Malnutrition, Hypertriglyceridaemia,&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Insomnia,</p><p>Depression</p></td><td colspan="2" style="vertical-align:top"><p>Confusional state, Panic attack, Depressed mood,</p><p>Libido decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Headache, Lethargy</p><p>Dizziness,</p><p>Parasthesia</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Aphasia, impairment, Syncope, disorder, disorder, peripheral</p></td><td style="vertical-align:top"><p>Memory</p><p>Ataxia,</p><p>Balance</p><p>Sensory Neuropathy</p></td><td style="vertical-align:top"><p>Toxic</p><p>leukoencephalopathy</p><p>(very rare)</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Lacrimation increased,</p><p>Conjunctivitis, Eye irritation</p></td><td colspan="2" style="vertical-align:top"><p>Visual acuity reduced,</p><p>Diplopia</p></td><td style="vertical-align:top"><p>Lacrimal duct &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stenosis</p><p>(rare), Corneal disorders(rare), keratitis</p><p>(rare), punctate keratitis</p><p>(rare)</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear &nbsp;&nbsp;&nbsp;&nbsp; and labyrinth disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>Vertigo, Ear pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><em>Cardiac </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Angina unstable, Angina pectoris, Myocardial ischaemia/infarction,</p><p>Atrial fibrillation, Arrhythmia,</p><p>Tachycardia, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus</p><p>tachycardia, Palpitations</p></td><td colspan="2" style="vertical-align:top"><p>Ventricular</p><p>(rare), QT prolongation</p><p>(rare), Torsade de pointes</p><p>(rare), Bradycardia (rare),</p><p>Vasospasm (rare)</p></td><td style="vertical-align:top"><p>fibrillation</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders </em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Thrombophlebitis</p></td><td style="vertical-align:top"><p>Deep vein thrombosis, Hypertension, Petechiae, Hypotension, Hot flush,</p><p>Peripheral coldness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, </em></p><p><em>thoracic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and mediastinal disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Dyspnoea,</p><p>Epistaxis, &nbsp;&nbsp;&nbsp;&nbsp; Cough,</p><p>Rhinorrhoea</p></td><td style="vertical-align:top"><p>Pulmonary &nbsp;&nbsp;&nbsp;&nbsp; embolism, Pneumothorax,</p><p>Haemoptysis, &nbsp;&nbsp;&nbsp;&nbsp; Asthma,</p><p>Dyspnoea exertional</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea,</p><p>Vomiting,</p><p>Nausea,</p><p>Stomatitis,</p><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage,</p><p>Constipation, Upper abdominal pain,</p><p>Dyspepsia,</p><p>Flatulence, &nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p></td><td style="vertical-align:top"><p>Intestinal obstruction, Ascites, Enteritis, Gastritis, Dysphagia, Abdominal pain lower, Oesophagitis,</p><p>Abdominal discomfort, Gastrooesophageal reflux disease, Colitis,</p><p>Blood in stool</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hyperbilirubinemia, Liver function test abnormalities</p></td><td style="vertical-align:top"><p>Jaundice</p></td><td colspan="2" style="vertical-align:top"><p>Hepatic &nbsp;&nbsp;&nbsp; failure</p><p>Cholestatic</p><p>(rare)</p></td><td style="vertical-align:top"><p>(rare), hepatitis</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><em>Skin &nbsp;&nbsp;&nbsp; and subcutaneous </em></p><p><em>tissue disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Palmar-plantar erythrodysaesthesia syndrome**&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Rash, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alopecia,</p><p>Erythema, Dry skin,</p><p>Pruritus, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin hyper-pigmentation, Rash macular, Skin desquamation, Dermatitis,</p><p>Pigmentation</p><p>disorder, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nail</p><p>disorder</p></td><td style="vertical-align:top"><p>Blister, Skin ulcer, Rash,</p><p>Urticaria,</p><p>Photosensitivity</p><p>reaction, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palmar erythema, Swelling face, Purpura, Radiation recall syndrome</p></td><td style="vertical-align:top"><p>Cutaneous lupus erythematosus (rare), Severe skin reactions such as Stevens-Johnson Syndrome and toxic</p><p>Epidermal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Necrolysis</p><p>(very rare) (see section</p><p>4.4.)</p></td></tr><tr><td style="vertical-align:top"><p><em>Muskuloskeletal and connective tissue disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Pain in extremity,</p><p>Back</p><p>Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;pain,</p></td><td style="vertical-align:top"><p>Joint swelling, Bone pain, Facial pain,</p><p>Musculoskeletal stiffness, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscular weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal &nbsp; and urinary disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hydronephrosis, Urinary incontinence,</p><p>Haematuria, Nocturia, Blood creatinine</p><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive </em></p><p><em>system &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and </em></p><p><em>breast disorders</em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vaginal haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and administration site conditions</em>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue,</p><p>Asthenia</p></td><td colspan="2" style="vertical-align:top"><p>Pyrexia, Oedema peripheral, Malaise,</p><p>Chest pain</p></td><td style="vertical-align:top"><p>Oedema, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills,</p><p>Influenza like illness,</p><p>Rigors, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body</p><p>temperature increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>** Based on the post-marketing experience, persistent or severe palmar-plantar erythrodysaesthesia syndrome can eventually lead to loss of fingerprints (see section 4.4) <em><u>Capecitabine in combination therapy:</u> </em>&nbsp;</p><p>Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3000 patients. ADRs are added to the appropriate frequency grouping (Very common or Common) according to the highest incidence seen in any of the major clinical trials and are only added when they were seen <strong>in addition to</strong> those seen with capecitabine monotherapy or seen at <strong>a higher frequency grouping</strong> compared to capecitabine monotherapy (see table 4). Uncommon ADRs reported for capecitabine in combination therapy are consistent with the ADRs reported for capecitabine monotherapy or reported for monotherapy with the combination medicinal product (in literature and/or respective summary of product characteristics).</p><p>Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory neuropathy with docetaxel or oxaliplatin, hypertension seen with bevacizumab); however an exacerbation by capecitabine therapy can not be excluded.</p><p>Table 5 Summary of related ADRs reported in patients treated with capecitabine in combination treatment <strong>in addition to</strong> those seen with capecitabine monotherapy or seen at <strong>a higher frequency grouping</strong> compared to capecitabine monotherapy</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very common</strong>&nbsp;</p><p><strong><em>All grades</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong>&nbsp;</p><p><strong><em>All grades</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Rare/Very Rare </strong>&nbsp;</p><p><strong>(Post-Marketing </strong></p><p><strong>Experience)</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Infections </em></p><p><em>infestations</em>&nbsp;</p></td><td style="vertical-align:top"><p><em>and </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Herpes zoster, Urinary tract infection, Oral candidiasis, Upper respiratory tract infection , Rhinitis, Influenza, <sup>+</sup>Infection,</p><p>Oral herpes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>+</p><p>Neutropenia,</p><p>+</p><p>Leucopenia,</p><p>+</p><p>Anaemia,</p><p>+</p><p>Neutropenic fever,</p><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Bone &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; marrow &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression,</p><p>+</p><p>Febrile Neutropenia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and </em></p><p><em>nutrition disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Appetite decreased</p></td><td style="vertical-align:top"><p>Hypokalaemia, Hyponatraemia,</p><p>Hypomagnesaemia,</p><p>Hypocalcaemia,</p><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-&nbsp;</p></td><td style="vertical-align:top"><p>Sleep disorder, Anxiety</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Paraesthesia,</p><p>Dysaesthesia, Peripheral neuropathy, Peripheral &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensory neuropathy, Dysgeusia,</p><p>Headache</p></td><td style="vertical-align:top"><p>Neurotoxicity, Tremor, Neuralgia, Hypersensitivity reaction, Hypoaesthesia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Lacrimation increased</p></td><td style="vertical-align:top"><p>Visual disorders, Dry eye, Eye pain, Visual impairment, Vision blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear &nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp; labyrinth </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Tinnitus, Hypoacusis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Atrial fibrillation, &nbsp;&nbsp;&nbsp;&nbsp; Cardiac ischaemia/infarction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><em>Vascular disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Lower limb oedema,</p><p>Hypertension,</p><p>+</p><p>Embolism thrombosis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>and</p></td><td style="vertical-align:top"><p>Flushing, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension,</p><p>Hypertensive crisis, Hot flush,</p><p>&nbsp;Phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal </em></p><p><em>system disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Sore</p><p>Dysaesthesia pharynx</p></td><td style="vertical-align:top"><p>throat,</p></td><td style="vertical-align:top"><p>&nbsp;Hiccups, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharyngolaryngeal pain, Dysphonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Constipation,</p><p>Dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Upper gastrointestinal haemorrhage, Mouth ulceration, Gastritis, Abdominal distension,</p><p>Gastroesophageal reflux disease, Oral pain, Dysphagia, Rectal haemorrhage, Abdominal pain lower, Oral dysaesthesia,</p><p>Paraesthesia oral, Hypoaesthesia oral, Abdominal discomfort</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary </em></p><p><em>disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic function abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous </em></p><p><em>tissue disorders</em>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia, disorder</p></td><td style="vertical-align:top"><p>Nail</p></td><td style="vertical-align:top"><p>&nbsp;Hyperhidrosis, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash erythematous, Urticaria, Night sweats</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue </em></p><p><em>disorders</em>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Myalgia, Arthralgia,</p><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Pain in jaw , Muscle spasms,</p><p>Trismus, Muscular weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal &nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp; urinary </em></p><p><em>disorder</em>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Haematuria, Proteinuria, Creatinine renal clearance</p><p>decreased, Dysuria</p></td><td style="vertical-align:top"><p>&nbsp;Acute</p><p>(rare)</p></td><td style="vertical-align:top"><p>renal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure</p><p>secondary to dehydration</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site </em></p><p><em>conditions</em>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Pyrexia, Weakness,</p><p>+</p><p>Lethargy, Temperature intolerance</p></td><td style="vertical-align:top"><p>&nbsp;Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, <sup>+</sup>Fever,</p><p>Infusion &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; related &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reaction,</p><p>Injection site reaction, Infusion site pain, Injection site pain</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Injury, poisoning and procedural complications</em>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Contusion</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>+</p><p>&nbsp;For each term, the frequency count was based on ADRs of all grades. For terms marked with a &ldquo;+&rdquo;, the frequency count was based on grade 3-4 ADRs. ADRs are added according to the highest incidence seen in any of the major combination trials.</p><p><u>Description of selected adverse reactions</u>&nbsp; <em><u>Hand-foot syndrome (see section 4.4):</u></em>&nbsp;</p><p>For the capecitabine dose of 1250 mg/m<sup>2</sup> twice daily on days 1 to 14 every 3 weeks, a frequency of 53% to 60% of all-grades HFS was observed in capecitabine monotherapy trials (comprising studies in adjuvant therapy in colon cancer, treatment of metastatic colorectal cancer, and treatment of breast cancer) and a frequency of 63% was observed in the capecitabine/docetaxel arm for the treatment of metastatic breast cancer. For the capecitabine dose of 1000 mg/m<sup>2</sup> twice daily on days 1 to 14 every 3 weeks, a frequency of 22% to 30% of all-grade HFS was observed in capecitabine combination therapy.&nbsp;</p><p>A meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine monotherapy or capecitabine in combination with different chemotherapy regimens in multiple indications (colon, colorectal, gastric and breast cancer) showed that HFS (all grades) occurred in 2066 (43%) patients after a median time of 239 [95% CI 201, 288] days after starting treatment with capecitabine. In all studies combined, the following covariates were statistically significantly associated with an increased risk of developing HFS: increasing capecitabine starting dose (gram), decreasing cumulative capecitabine dose (0.1*kg), increasing relative dose intensity in the first six weeks, increasing duration of study treatment (weeks), increasing age (by 10 year increments), female gender, and good ECOG performance status at baseline (0 versus &ge;1).</p><p><em><u>Diarrhoea (see section 4.4):</u></em>&nbsp;</p><p>Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.&nbsp;</p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, the following covariates were statistically significantly associated with an increased risk of developing diarrhoea: increasing capecitabine starting dose (gram), increasing duration of study treatment (weeks), increasing age (by 10 year increments), and female gender. The following covariates were statistically significantly associated with a decreased risk of developing diarrhoea: increasing cumulative capecitabine dose (0.1*kg) and increasing relative dose intensity in the first six weeks.&nbsp;</p><p><em><u>Cardiotoxicity (see section 4.4):</u></em>&nbsp;</p><p>In addition to the ADRs described in tables 4 and 5, the following ADRs with an incidence of less than 0.1% were associated with the use of capecitabine monotherapy based on a pooled analysis from clinical safety data from 7 clinical trials including 949 patients (2 phase III and 5 phase II clinical trials in metastatic colorectal cancer and metastatic breast cancer): cardiomyopathy, cardiac failure, sudden death, and ventricular extrasystoles.&nbsp;</p><p><em><u>Encephalopathy:</u></em>&nbsp;</p><p>In addition to the ADRs described in tables 4 and 5, and based on the above pooled analysis from clinical safety data from 7 clinical trials, encephalopathy was also associated with the use of capecitabine monotherapy with an incidence of less than 0.1%.</p><p><u>Exposure to crushed or cut capecitabine tablets:</u></p><p>In the instance of exposure to crushed or cut capecitabine tablets, the following adverse drug reactions have been reported: eye irritation, eye swelling, skin rash, headache, paresthesia, diarrhea, nausea, gastric irritation, and vomiting.</p><p>Special populations&nbsp;</p><p><em><u>Elderly patients (see section 4.2):</u></em>&nbsp;</p><p>An analysis of safety data in patients &ge;60 years of age treated with capecitabine monotherapy and an analysis of patients treated with capecitabine plus docetaxel combination therapy showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions and treatmentrelated serious adverse reactions compared to patients &lt;60 years of age. Patients &ge;60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients &lt;60 years of age.&nbsp;</p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, increasing age (by 10 year increments) was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.&nbsp;</p><p><u>Gender</u>&nbsp;</p><p>The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, female gender was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.&nbsp;</p><p><em><u>Patients with renal impairment (see section 4.2, 4.4, and 5.2):</u></em>&nbsp;</p><p>An analysis of safety data in patients treated with capecitabine monotherapy (colorectal cancer) with baseline renal impairment showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions compared to patients with normal renal function (36% in patients without renal impairment n=268, vs. 41% in mild n=257 and 54% in moderate n=59, respectively) (see section 5.2). Patients with moderately impaired renal function show an increased rate of dose reduction (44%) vs. 33% and 32% in patients with no or mild renal impairment and an increase in early withdrawals from treatment (21% withdrawals during the first two cycles) vs. 5% and 8% in patients with no or mild renal impairment.</p><p>&nbsp;Reporting of suspected adverse reactions&nbsp;</p><p>&nbsp;If you get any side effects, talk to your doctor or pharmacist. This includes any possible side&nbsp;&nbsp;&nbsp;&nbsp; effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />oWebsite: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;<strong><em>o &nbsp;Other </em></strong><strong><em>GCC States: </em></strong></p><p>&nbsp;Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The manifestations of acute overdose include nausea, vomiting, diarrhoea, mucositis, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management of overdose should include customary therapeutic and supportive medical interventions aimed at correcting the presenting clinical manifestations and preventing their possible complications.<strong>&nbsp; </strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: cytostatic (antimetabolite), ATC code: L01BC06</p><p>Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-fluorouracil (5-FU). Capecitabine is activated via several enzymatic steps (see section 5.2). The enzyme involved in the final conversion to 5FU, thymidine phosphorylase (ThyPase), is found in tumour tissues, but also in normal tissues, albeit usually at lower levels. In human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel.</p><p>There is evidence that the metabolism of 5-FU in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, thereby interfering with the synthesis of deoxyribonucleic acid (DNA). The incorporation of 5-FU also leads to inhibition of RNA and protein synthesis. Since DNA and RNA are essential for cell division and growth, the effect of 5FU may be to create a thymidine deficiency that provokes unbalanced growth and death of a cell. The effects of DNA and RNA deprivation are most marked on those cells which proliferate more rapidly and which metabolise 5-FU at a more rapid rate.&nbsp;</p><p><u>Colon and colorectal cancer:</u>&nbsp;</p><p><em>Monotherapy with capecitabine in adjuvant colon cancer</em>&nbsp;</p><p>Data from one multicentre, randomised, controlled phase III clinical trial in patients with stage III (Dukes&#39; C) colon cancer supports the use of capecitabine for the adjuvant treatment of patients with colon cancer (XACT Study; M66001). In this trial, 1987 patients were randomised to treatment with capecitabine (1250 mg/m<sup>2</sup> twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles for 24 weeks) or 5-FU and leucovorin (Mayo Clinic regimen: 20 mg/m<sup>2</sup> leucovorin IV followed by 425 mg/m<sup>2</sup> intravenous bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks). Capecitabine was at least equivalent to IV 5-FU/LV in disease-free survival in per protocol population (hazard ratio 0.92; 95% CI 0.80-1.06). In the all-randomised population, tests for difference of capecitabine vs 5-FU/LV in disease-free and overall survival showed hazard ratios of 0.88 (95% CI 0.77 &ndash; 1.01; p = 0.068) and 0.86 (95% CI 0.74 &ndash; 1.01; p = 0.060), respectively. The median follow up at the time of the analysis was 6.9 years. In a preplanned multivariate Cox analysis, superiority of capecitabine compared with bolus 5-FU/LV was demonstrated. The following factors were pre-specified in the statistical analysis plan for inclusion in the model: age, time from surgery to randomization, gender, CEA levels at baseline, lymph nodes at baseline, and country. In the all-randomised population, capecitabine was shown to be superior to 5FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p =</p><p>0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).&nbsp;</p><p><em>Combination therapy in adjuvant colon cancer</em>&nbsp;</p><p>Data from one multicentre, randomised, controlled phase 3 clinical trial in patients with stage III (Dukes&#39; C) colon cancer supports the use of capecitabine in combination with oxaliplatin (XELOX) for the adjuvant treatment of patients with colon cancer (NO16968 study). In this trial, 944 patients were randomised to 3-week cycles for 24 weeks with capecitabine (1000 mg/m<sup>2</sup> twice daily for 2 weeks followed by a 1-week rest period) in combination with oxaliplatin (130 mg/m<sup>2</sup> intravenous infusion over 2-hours on day 1 every 3 weeks); 942 patients were randomised to bolus 5-FU and leucovorin. In the primary analysis for DFS in the ITT population, XELOX was shown to be significantly superior to 5-FU/LV (HR=0.80, 95% CI=[0.69; 0.93]; p=0.0045). The 3 year DFS rate was 71% for XELOX versus 67% for 5-FU/LV. The analysis for the secondary endpoint of RFS supports these results with a HR of 0.78 (95% CI=[0.67; 0.92]; p=0.0024) for XELOX vs. 5-FU/LV. XELOX showed a trend towards superior OS with a HR of 0.87 (95% CI=[0.72; 1.05]; p=0.1486) which translates into a 13% reduction in risk of death. The 5 year OS rate was 78% for XELOX versus 74% for 5-FU/LV. The efficacy data is based on a median observation time of 59 months for OS and 57 months for DFS. The rate of withdrawal due to adverse events was higher in the XELOX combination therapy arm (21%) as compared with that of the 5-FU/LV monotherapy arm (9%) in the ITT population.</p><p><em>Monotherapy with capecitabine in metastatic colorectal cancer</em>&nbsp;</p><p>Data from two identically-designed, multicentre, randomised, controlled phase III clinical trials (SO14695; SO14796) support the use of capecitabine for first line treatment of metastatic colorectal cancer. In these trials, 603 patients were randomised to treatment with capecitabine (1250 mg/m<sup>2</sup> twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles). 604 patients were randomised to treatment with 5-FU and leucovorin (Mayo regimen: 20 mg/m<sup>2</sup> leucovorin intravenous followed by 425 mg/m<sup>2</sup> intravenous bolus 5-FU, on days 1 to 5, every 28 days). The overall objective response rates in the all-randomised population (investigator assessment) were 25.7% (capecitabine) vs. 16.7% (Mayo regimen); p &lt;0.0002. The median time to progression was 140 days (capecitabine) vs. 144 days (Mayo regimen). Median survival was 392 days (capecitabine) vs. 391 days (Mayo regimen). Currently, no comparative data are available on capecitabine monotherapy in colorectal cancer in comparison with first line combination regimens.</p><p><em>Combination therapy in first-line treatment of metastatic colorectal cancer</em>&nbsp;</p><p>Data from a multicentre, randomised, controlled phase III clinical study (NO16966) support the use of capecitabine in combination with oxaliplatin or in combination with oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. The study contained two parts: an initial 2-arm part in which 634 patients were randomised to two different treatment groups, including XELOX or FOLFOX-4, and a subsequent 2x2 factorial part in which 1401 patients were randomised to four different treatment groups, including XELOX plus placebo, FOLFOX-4 plus placebo, XELOX plus bevacizumab, and FOLFOX-4 plus bevacizumab. See table 6 for treatment regimens.</p><p>Table 6 Treatment regimens in study NO16966 (mCRC)&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Treatment</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Starting Dose</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Schedule</strong>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>FOLFOX-4&nbsp;</p><p>or&nbsp;</p><p>FOLFOX-4</p><p>Bevacizumab</p></td><td rowspan="3" style="vertical-align:top"><p>+</p></td><td colspan="2" style="vertical-align:top"><p>Oxaliplatin</p></td><td style="vertical-align:top"><p>85 mg/m<sup>2</sup> intravenous 2</p><p>hr</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;Oxaliplatin on Day 1, every 2 weeks</p><p>Leucovorin on Days 1 and 2, every 2&nbsp; weeks</p><p>5-fluorouracil &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intravenous</p><p>bolus/infusion, each on Days 1 and 2,</p><p>&nbsp;</p><p>every 2 weeks</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>&nbsp;</sup>Leucovorin</p></td><td style="vertical-align:top"><p>200 mg/m<sup>2</sup> intravenous 2</p><p>hr</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>5-Fluorouracil</p></td><td style="vertical-align:top"><p>400 mg/m<sup>2</sup> intravenous bolus, followed by 600</p></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>mg/ m<sup>2</sup> intravenous 22 hr</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>Bevacizumab</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>5 mg/kg intravenous 30-</p><p>90 mins</p></td><td style="vertical-align:top"><p>Day 1, prior to FOLFOX-4, every 2 weeks</p></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>XELOX&nbsp;</p><p>or</p><p>XELOX+</p><p>Bevacizumab</p></td><td style="vertical-align:top"><p>Oxaliplatin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>130 mg/m<sup>2</sup> intravenous 2 hr</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;Oxaliplatin on Day 1, every 3 weeks</p><p>Capecitabine oral twice daily for 2&nbsp; weeks (followed by 1 week offtreatment)</p></td></tr><tr><td style="vertical-align:top"><p>Capecitabine</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1000 mg/m<sup>2</sup> oral twice</p><p>daily</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>Bevacizumab</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>7.5 &nbsp;&nbsp;&nbsp; mg/kg &nbsp;&nbsp;&nbsp; intravenous</p><p>30-90 mins</p></td><td style="vertical-align:top"><p>Day 1, prior to XELOX, every 3 weeks</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>5-Fluorouracil: intravenous bolus injection immediately after leucovorin</p></td></tr></tbody></table><p>Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival in the eligible patient population and the intent-to-treat population (see table 7). The results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival (see table 7). A comparison of XELOX plus bevacizumab versus FOLFOX-4 plus bevacizumab was a pre-specified exploratory analysis. In this treatment subgroup comparison, XELOX plus bevacizumab was similar compared to FOLFOX-4 plus bevacizumab in terms of progression-free survival (hazard ratio 1.01; 97.5% CI 0.84 - 1.22). The median follow up at the time of the primary analyses in the intent-to-treat population was 1.5 years; data from analyses following an additional 1 year of follow up are also included in table 7. However, the on-treatment PFS analysis did not confirm the results of the general PFS and OS analysis: the hazard ratio of XELOX versus FOLFOX-4 was 1.24 with 97.5% CI 1.07 - 1.44. Although sensitivity analyses show that differences in regimen schedules and timing of tumor assessments impact the on-treatment PFS analysis, a full explanation for this result has not been found.</p><p>Table 7 Key efficacy results for the non-inferiority analysis of Study NO16966&nbsp;</p><p><strong>PRIMARY ANALYSIS</strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>XELOX/XELOX+P/ </strong></p><p><strong>XELOX+BV</strong>&nbsp;</p><p><strong>(EPP*: N=967; ITT**: N=1017)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>FOLFOX-4/FOLFOX-4+P/ </strong></p><p><strong>FOLFOX-4+BV</strong>&nbsp;</p><p><strong>(EPP*: N = 937; ITT**: N= </strong></p><p><strong>1017)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Population</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Median Time to Event (Days) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>HR</strong>&nbsp;</p><p><strong>(97.5% CI)</strong>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EPP</p><p>ITT</p></td><td style="vertical-align:top"><p>241</p><p>244</p></td><td style="vertical-align:top"><p>259&nbsp;</p><p>259</p></td><td style="vertical-align:top"><p>1.05 (0.94; 1.18)</p><p>1.04 (0.93; 1.16)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter: Overall Survival</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EPP</p><p>ITT</p></td><td style="vertical-align:top"><p>577</p><p>581</p></td><td style="vertical-align:top"><p>549</p><p>553</p></td><td style="vertical-align:top"><p>0.97 (0.84; 1.14)</p><p>0.96 (0.83; 1.12)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ADDITIONAL 1 YEAR OF FOLLOW UP</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Population</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Median Time to Event (Days) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>HR</strong>&nbsp;</p><p><strong>(97.5% CI)</strong>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EPP</p><p>ITT</p></td><td style="vertical-align:top"><p>242&nbsp;</p><p>244</p></td><td style="vertical-align:top"><p>259</p><p>259</p></td><td style="vertical-align:top"><p>1.02 (0.92; 1.14)</p><p>1.01 (0.91; 1.12)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter: Overall Survival</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EPP</p><p>ITT</p></td><td style="vertical-align:top"><p>600</p><p>602</p></td><td style="vertical-align:top"><p>594</p><p>596</p></td><td style="vertical-align:top"><p>1.00 (0.88; 1.13)</p><p>0.99 (0.88; 1.12)</p></td></tr></tbody></table><p>*EPP=eligible patient population; **ITT=intent-to-treat population</p><p>In a randomised, controlled phase III study (CAIRO), the effect of using capecitabine at a starting dose of 1000 mg/m<sup>2</sup> for 2 weeks every 3 weeks in combination with irinotecan for the first-line treatment of patients with metastatic colorectal cancer was studied. 820 Patients were randomised to receive either sequential treatment (n=410) or combination treatment (n=410).</p><p>Sequential treatment consisted of first-line capecitabine (1250 mg/m<sup>2</sup> twice daily for 14 days), second-line irinotecan (350 mg/m<sup>2</sup> on day 1), and third-line combination of capecitabine (1000 mg/m<sup>2</sup> twice daily for 14 days) with oxaliplatin (130 mg/m<sup>2</sup> on day 1). Combination treatment consisted of first-line capecitabine (1000 mg/m<sup>2</sup> twice daily for 14 days) combined with irinotecan (250 mg /m<sup>2</sup> on day 1) (XELIRI) and second-line capecitabine (1000 mg/m<sup>2</sup> twice daily for 14 days) plus oxaliplatin (130 mg/m2 on day 1). All treatment cycles were administered at intervals of 3 weeks. In first-line treatment the median progression-free survival in the intentto-treat population was 5.8 months (95%CI 5.1 - 6.2 months) for capecitabine monotherapy and 7.8 months (95%CI 7.0 - 8.3 months; p=0.0002) for XELIRI. However this was associated with an increased incidence of gastrointestinal toxicity and neutropenia during first-line treatment with XELIRI (26% and 11% for XELIRI and first line capecitabine respectively).</p><p>The XELIRI has been compared with 5-FU + irinotecan (FOLFIRI) in three randomised studies in patients with metastatic colorectal cancer. The XELIRI regimens included capecitabine 1000 mg/m<sup>2</sup> twice daily on days 1 to 14 of a three-week cycle combined with irinotecan 250 mg/m<sup>2</sup> on day1. In the largest study (BICC-C), patients were randomised to receive either open label FOLFIRI (n=144), bolus 5-FU (mIFL) (n=145) or XELIRI (n=141) and were additionally randomised to receive either double-blind treatment with celecoxib or placebo. Median PFS was 7.6 months for FOLFIRI, 5.9 months for mIFL (p=0.004) for the comparison with FOLFIRI), and 5.8 months for XELIRI (p=0.015). Median OS was 23.1 months for FOLFIRI, 17.6 months for mIFL (p=0.09), and 18.9 months for XELIRI (p=0.27). Patients treated with XELIRI experienced excessive gastrointestinal toxicity compared with FOLFIRI (diarrhoea 48% and 14% for XELIRI and FOLFIRI respectively).</p><p>In the EORTC study patients were randomised to receive either open label FOLFIRI (n=41) or XELIRI (n=44) with additional randomisation to either double-blind treatment with celecoxib or placebo. Median PFS and overall survival (OS) times were shorter for XELIRI versus FOLFIRI (PFS 5.9 versus 9.6 months and OS 14.8 versus 19.9 months), in addition to which excessive rates of diarrhoea were reported in patients receiving the XELIRI regimen (41% XELIRI, 5.1% FOLFIRI).&nbsp;</p><p>In the study published by Skof et al, patients were randomised to receive either FOLFIRI or XELIRI . Overall response rate was 49% in the XELIRI and 48% in the FOLFIRI arm (p=0.76). At the end of treatment, 37% of patients in the XELIRI and 26% of patients in the FOLFIRI arm were without evidence of the disease (p=0.56). Toxcity was similar between treatments with the exception of neutropenia reported more commonly in patients treated with FOLFIRI.</p><p>Montagnani et al used the results from the above three studies to provide an overall analysis of randomised studies comparing FOLFIRI and XELIRI treatment regimens in the treatment of mCRC. A significant reduction in the risk of progression was associated with FOLFIRI (HR, 0.76; 95%CI, 0.62-0.95; P &lt;0.01), a result partly due to poor tolerance to the XELIRI regimens used.</p><p>Data from a randomised clinical study (Souglakos et al, 2012) comparing FOLFIRI + bevacizumab with XELIRI + bevacizumab showed no significant differences in PFS or OS between treatments. Patients were randomised to receive either FOLFIRI plus bevacizumab (Arm-A, n=167) or XELIRI plus bevacizumab (Arm-B, n-166). For Arm B, the XELIRI regimen used capecitabine 1000 mg/m<sup>2</sup> twice daily for 14 days + irinotecan 250 mg/m<sup>2</sup> on day 1. Median progression-free survival (PFS) was 10.0 and 8.9 months; p=0.64, overall survival 25.7 and 27.5 months; p=0.55 and response rates 45.5 and 39.8%; p=0.32 for FOLFIRI-Bev and XELIRI-Bev, respectively. Patients treated with XELIRI + bevacizumab reported a significantly higher incidence of diarrhoea, febrile neutropenia and hand-foot skin reactions than patients treated with FOLFIRI + bevacizumab with significantly increased treatment delays, dose reductions and treatment discontinuations.</p><p>Data from a multicentre, randomised, controlled phase II study (AIO KRK 0604) supports the use of capecitabine at a starting dose of 800 mg/m<sup>2 </sup>for 2 weeks every 3 weeks in combination with irinotecan and bevacizumab for the first-line treatment of patients with metastatic colorectal cancer. 120 Patients were randomised to a modified XELIRI regimen with capecitabine 800 mg/m<sup>2 </sup>twice daily for two weeks followed by a 7-day rest period), irinotecan (200 mg/m<sup>2</sup> as a 30 minute infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks ; 127 patients were randomised to treatment with capecitabine (1000 mg/m<sup>2</sup> twice daily for two weeks followed by a 7-day rest period), oxaliplatin (130 mg/m<sup>2</sup> as a 2 hour infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks). Following a mean duration of follow-up for the study population of 26.2 months, treatment responses were as shown below:&nbsp;</p><p>Table 8 Key efficacy results for AIO KRK study</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>XELOX + bevacizumab</em> </strong>&nbsp;</p><p><strong><em>(ITT: N=127)</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>Modified &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; XELIRI+ bevacizumab</em> </strong>&nbsp;</p><p><strong><em>(ITT: N= 120)</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>Hazard ratio</em> </strong>&nbsp;</p><p><strong><em>95% CI</em> </strong>&nbsp;</p><p><strong><em>P value</em> </strong>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><em>Progression-free Survival after 6 months</em> </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ITT</em> </strong>&nbsp;</p><p><strong><em>95% CI</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>76%</em> </strong>&nbsp;<strong><em>69 - 84%</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>84% </em></strong>&nbsp;<strong><em>77 - 90%</em> </strong>&nbsp;</p></td><td><p><strong><em>-</em> </strong>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><em>Median progression free survival</em> </strong>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><!--[if gte vml 1]><v:group id="Group_x0020_65306" o:spid="_x0000_s1032"
   style='position:absolute;left:0;text-align:left;margin-left:87.85pt;
   margin-top:-4.4pt;width:.7pt;height:65.15pt;z-index:251659264;
   mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
   coordsize="91,8275" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_68660" o:spid="_x0000_s1033" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAWBbsaxAAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NisIw
FIX3wrxDuAPuNJ0Bi3aMIoIwurC06qwvzbWt09yUJmp9e7MQXB7OH9982ZtG3KhztWUFX+MIBHFh
dc2lguNhM5qCcB5ZY2OZFDzIwXLxMZhjou2dM7rlvhRhhF2CCirv20RKV1Rk0I1tSxy8s+0M+iC7
UuoO72HcNPI7imJpsObwUGFL64qK//xqFKxP+q/d7Hdum/nV7MiXdJJmqVLDz371A8JT79/hV/tX
K4incRwAAk5AAbl4AgAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhABYFuxrEAAAA3gAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_68661" o:spid="_x0000_s1034" style='position:absolute;
    top:198;width:91;height:8077;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,807720" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,807720l,807720,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,807720"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="87" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_65307" o:spid="_x0000_s1029" style='position:absolute;
   left:0;text-align:left;margin-left:258.9pt;margin-top:-4.4pt;width:.7pt;
   height:65.15pt;z-index:251660288;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,8275" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_68664" o:spid="_x0000_s1030" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_68665" o:spid="_x0000_s1031" style='position:absolute;
    top:198;width:91;height:8077;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,807720" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,807720l,807720,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,807720"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="87" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:group
   id="Group_x0020_65308" o:spid="_x0000_s1026" style='position:absolute;
   left:0;text-align:left;margin-left:388.5pt;margin-top:-4.4pt;width:.7pt;
   height:65.15pt;z-index:251661312;mso-position-horizontal-relative:text;
   mso-position-vertical-relative:text' coordsize="91,8275" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_68668" o:spid="_x0000_s1027" style='position:absolute;
    width:91;height:198;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,19812" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDoc7ccwgAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9Ni8Iw
EL0L+x/CLHjTdBcs2jWKCMLqwdKqex6asa3bTEoTtf57cxA8Pt73fNmbRtyoc7VlBV/jCARxYXXN
pYLjYTOagnAeWWNjmRQ8yMFy8TGYY6LtnTO65b4UIYRdggoq79tESldUZNCNbUscuLPtDPoAu1Lq
Du8h3DTyO4piabDm0FBhS+uKiv/8ahSsT/qv3ex3bpv51ezIl3SSZqlSw89+9QPCU+/f4pf7VyuI
p3Ec9oY74QrIxRMAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDoc7ccwgAAAN4AAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" path="m,l9144,r,19812l,19812,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,19812"/>
   </v:shape><v:shape id="Shape_x0020_68669" o:spid="_x0000_s1028" style='position:absolute;
    top:198;width:91;height:8077;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="9144,807720" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCGAnHkwgAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/RagIx
FETfC/5DuIJvNWsti12NIoLgm9T2Ay6b6+5icrMkMbv9eyMIfRxm5gyz2Y3WiEQ+dI4VLOYFCOLa
6Y4bBb8/x/cViBCRNRrHpOCPAuy2k7cNVtoN/E3pEhuRIRwqVNDG2FdShroli2HueuLsXZ23GLP0
jdQehwy3Rn4URSktdpwXWuzp0FJ9u9ytguG+OFpv0v6cPjWegmGXeKnUbDru1yAijfE//GqftIJy
VZZf8LyTr4DcPgAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCGAnHkwgAAAN4AAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" path="m,l9144,r,807720l,807720,,e" fillcolor="#7b7b7b" stroked="f"
    strokeweight="0">
    <v:stroke endcap="round"/>
    <v:path arrowok="t" textboxrect="0,0,9144,807720"/>
   </v:shape><w:wrap type="square"/>
  </v:group><![endif]--><img width="1" height="87" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><strong><em>ITT</em> </strong>&nbsp;<strong><em>10.4 months</em> </strong>&nbsp;<strong><em>12.1 months</em> </strong>&nbsp;<strong><em>0.93</em> </strong>&nbsp;</p><p><strong><em>95% CI</em> </strong>&nbsp;<strong><em>9.0 - 12.0</em> </strong>&nbsp;<strong><em>10.8 - 13.2</em> </strong>&nbsp;<strong><em>0.82 - 1.07</em> </strong>&nbsp;</p><p><strong><em>P=0.30</em> </strong>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><em>Median overall survival</em> </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ITT</em> </strong>&nbsp;</p><p><strong><em>95% CI</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>24.4 months</em> </strong>&nbsp;</p><p><strong><em>19.3 - 30.7</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>25.5 months</em> </strong>&nbsp;</p><p><strong><em>21.0 - 31.0</em> </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong><em>0.90</em> </strong>&nbsp;</p><p><strong><em>0.68 - 1.19</em> </strong>&nbsp;<strong><em>P=0.45</em> </strong>&nbsp;</p></td></tr></tbody></table><p><em>Combination therapy in second-line treatment of metastatic colorectal cancer</em>&nbsp;</p><p>Data from a multicentre, randomised, controlled phase III clinical study (NO16967) support the use of capecitabine in combination with oxaliplatin for the second-line treatment of metastastic colorectal cancer. In this trial, 627 patients with metastatic colorectal carcinoma who have received prior treatment with irinotecan in combination with a fluoropyrimidine regimen as first line therapy were randomised to treatment with XELOX or FOLFOX-4. For the dosing schedule of XELOX and FOLFOX-4 (without addition of placebo or bevacizumab), refer to table 6. XELOX was demonstrated to be non-inferior to FOLFOX-4 in terms of progression-free survival in the per-protocol population and intent-to-treat population (see table 9). The results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival (see table 9). The median follow up at the time of the primary analyses in the intent-to-treat population was 2.1 years; data from analyses following an additional 6 months of follow up are also included in table 9.&nbsp;</p><p>Table 9 Key efficacy results for the non-inferiority analysis of Study NO16967&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>PRIMARY ANALYSIS</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>XELOX</strong>&nbsp;</p><p><strong>(PPP*: N=251; ITT**: N=313)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>FOLFOX-4</strong>&nbsp;</p><p><strong>(PPP*: N = 252; ITT**: N= 314)</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Population</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Median Time to Event (Days) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>HR</strong>&nbsp;</p><p><strong>(95% CI)</strong>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PPP</p><p>ITT</p></td><td style="vertical-align:top"><p>154</p><p>144</p></td><td style="vertical-align:top"><p>168</p><p>146</p></td><td style="vertical-align:top"><p>1.03 (0.87; 1.24)</p><p>0.97 (0.83; 1.14)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter: Overall Survival</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PPP</p><p>ITT</p></td><td style="vertical-align:top"><p>388</p><p>363</p></td><td style="vertical-align:top"><p>401</p><p>382</p></td><td style="vertical-align:top"><p>1.07 (0.88; 1.31)</p><p>1.03 (0.87; 1.23)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ADDITIONAL 6 MONTHS OF FOLLOW UP</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Population</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Median Time to Event (Days) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>HR</strong>&nbsp;</p><p><strong>(95% CI)</strong>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PPP</p><p>ITT</p></td><td style="vertical-align:top"><p>154</p><p>143</p></td><td style="vertical-align:top"><p>166</p><p>146</p></td><td style="vertical-align:top"><p>1.04 (0.87; 1.24)</p><p>0.97 (0.83; 1.14)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Parameter: Overall Survival</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PPP</p><p>ITT</p></td><td style="vertical-align:top"><p>393</p><p>363</p></td><td style="vertical-align:top"><p>402</p><p>382</p></td><td style="vertical-align:top"><p>1.05 (0.88; 1.27)</p><p>1.02 (0.86; 1.21)</p></td></tr></tbody></table><p>*PPP=per-protocol population; **ITT=intent-to-treat population</p><p><u>Advanced gastric cancer:</u>&nbsp;</p><p>Data from a multicentre, randomised, controlled phase III clinical trial in patients with advanced gastric cancer supports the use of capecitabine for the first-line treatment of advanced gastric cancer (ML17032). In this trial, 160 patients were randomised to treatment with capecitabine (1000 mg/m<sup>2</sup> twice daily for 2 weeks followed by a 7-day rest period) and cisplatin (80 mg/m<sup>2</sup> as a 2-hour infusion every 3 weeks). A total of 156 patients were randomised to treatment with 5FU (800 mg/m<sup>2</sup> per day, continuous infusion on days 1 to 5 every 3 weeks) and cisplatin (80 mg/m<sup>2</sup> as a 2-hour infusion on day 1, every 3 weeks). Capecitabine in combination with cisplatin was non-inferior to 5-FU in combination with cisplatin in terms of progression-free survival in the per protocol analysis (hazard ratio 0.81; 95% CI 0.63 - 1.04). The median progression-free survival was 5.6 months (capecitabine + cisplatin) versus 5.0 months (5-FU + cisplatin). The hazard ratio for duration of survival (overall survival) was similar to the hazard ratio for progression-free survival (hazard ratio 0.85; 95% CI 0.64 - 1.13). The median duration of survival was 10.5 months (capecitabine + cisplatin) versus 9.3 months (5-FU + cisplatin).</p><p>Data from a randomised multicentre, phase III study comparing capecitabine to 5-FU and oxaliplatin to cisplatin in patients with advanced gastric cancer supports the use of capecitabine for the first-line treatment of advanced gastric cancer (REAL-2). In this trial, 1002 patients were randomised in a 2x2 factorial design to one of the following 4 arms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ECF: epirubicin (50 mg/ m<sup>2</sup> as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m<sup>2</sup> as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m<sup>2</sup> daily given by continuous infusion via a central line).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ECX: epirubicin (50 mg/m<sup>2</sup> as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m<sup>2</sup> as a two hour infusion on day 1 every 3 weeks), and capecitabine (625 mg/m<sup>2</sup> twice daily continuously).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EOF: epirubicin (50 mg/m<sup>2</sup> as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m<sup>2</sup> given as a 2 hour infusion on day 1 every three weeks), and 5-FU (200 mg/m<sup>2</sup> daily given by continuous infusion via a central line).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EOX: epirubicin (50 mg/m<sup>2</sup> as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m<sup>2</sup> given as a 2 hour infusion on day 1 every three weeks), and capecitabine (625 mg/m<sup>2</sup> twice daily continuously).&nbsp;</p><p>The primary efficacy analyses in the per protocol population demonstrated non-inferiority in overall survival for capecitabine- vs 5-FU-based regimens (hazard ratio 0.86; 95% CI 0.8 - 0.99) and for oxaliplatin- vs cisplatin-based regimens (hazard ratio 0.92; 95% CI 0.80 - 1.1). The median overall survival was 10.9 months in capecitabine-based regimens and 9.6 months in 5FU based regimens. The median overall survival was 10.0 months in cisplatin-based regimens and 10.4 months in oxaliplatin-based regimens.&nbsp;</p><p>Capecitabine has also been used in combination with oxaliplatin for the treatment of advanced gastric cancer. Studies with capecitabine monotherapy indicate that capecitabine has activity in advanced gastric cancer.</p><p>Colon, colorectal and advanced gastric cancer: meta-analysis&nbsp;</p><p>A meta-analysis of six clinical trials (studies SO14695, SO14796, M66001, NO16966, NO16967, M17032) supports capecitabine replacing 5-FU in mono- and combination treatment in gastrointestinal cancer. The pooled analysis includes 3097 patients treated with capecitabinecontaining regimens and 3074 patients treated with 5-FU-containing regimens. Median overall survival time was 703 days (95% CI: 671; 745) in patients treated with capecitabine-containing regimens and 683 days (95% CI: 646; 715) in patients treated with 5-FU-containing regimens. The hazard ratio for overall survival was 0.94 (95% CI: 0.89; 1.00, p=0.0489) indicating that capecitabine-containing regimens are non-inferior to 5-FU-containing regimens.</p><p><u>Breast cancer:</u>&nbsp;</p><p><u>Combination therapy with capecitabine and docetaxel in locally advanced or metastatic breast</u> <u>cancer</u>&nbsp;</p><p>Data from one multicentre, randomised, controlled phase III clinical trial support the use of capecitabine in combination with docetaxel for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an anthracycline. In this trial, 255 patients were randomised to treatment with capecitabine (1250 mg/m<sup>2</sup> twice daily for 2 weeks followed by 1-week rest period and docetaxel 75 mg/m<sup>2</sup> as a 1 hour intravenous infusion every 3 weeks). 256 patients were randomised to treatment with docetaxel alone (100 mg/m<sup>2 </sup>as a 1 hour intravenous infusion every 3 weeks). Survival was superior in the capecitabine + docetaxel combination arm (p=0.0126). Median survival was 442 days (capecitabine + docetaxel) vs. 352 days (docetaxel alone). The overall objective response rates in the allrandomised population (investigator assessment) were 41.6% (capecitabine + docetaxel) vs. 29.7% (docetaxel alone); p = 0.0058. Time to progressive disease was superior in the capecitabine + docetaxel combination arm (p&lt;0.0001). The median time to progression was 186 days (capecitabine + docetaxel) vs. 128 days (docetaxel alone).&nbsp;</p><p><u>Monotherapy with capecitabine after failure of taxanes, anthracycline containing chemotherapy,</u> <u>and for whom anthracycline therapy is not indicated</u>&nbsp;</p><p>Data from two multicentre phase II clinical trials support the use of capecitabine monotherapy for treatment of patients after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. In these trials, a total of 236 patients were treated with capecitabine (1250 mg/m<sup>2</sup> twice daily for 2 weeks followed by 1-week rest period). The overall objective response rates (investigator assessment) were 20% (first trial) and 25% (second trial). The median time to progression was 93 and 98 days. Median survival was 384 and 373 days.&nbsp;</p><p><u>All indications:</u>&nbsp;</p><p>A meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine monotherapy or capecitabine in combination with different chemotherapy regimens in multiple indications (colon, colorectal, gastric and breast cancer) showed that patients on capecitabine who developed hand-foot syndrome (HFS) had a longer overall survival compared to patients who did not develop HFS: median overall survival 1100 days (95% CI 1007;1200) vs 691 days (95% CI 638;754) with a hazard ratio of 0.61 (95% CI 0.56; 0.66).&nbsp;</p><p><u>Paediatric population:</u>&nbsp;</p><p>The European Medicines Agency has waived the obligation to conduct studies with Capecitabine Tablets in all subsets of the paediatric population in adenocarcinoma of the colon and rectum, gastric adenocarcinoma and breast carcinoma (see section 4.2 for information on paediatric use).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of capecitabine have been evaluated over a dose range of 502-3514 mg/m<sup>2</sup>/day. The parameters of capecitabine, 5&#39;-deoxy-5-fluorocytidine (5&#39;-DFCR) and 5&#39;-deoxy5-fluorouridine (5&#39;-DFUR) measured on days 1 and 14 were similar. The AUC of 5-FU was 30%-35% higher on day 14. Capecitabine dose reduction decreases systemic exposure to 5-FU more than dose-proportionally, due to non-linear pharmacokinetics for the active metabolite.</p><p>Absorption&nbsp;</p><p>After oral administration, capecitabine is rapidly and extensively absorbed, followed by extensive conversion to the metabolites, 5&#39;-DFCR and 5&#39;-DFUR. Administration with food decreases the rate of capecitabine absorption, but only results in a minor effect on the AUC of 5&#39;DFUR, and on the AUC of the subsequent metabolite 5-FU. At the dose of 1250 mg/m<sup>2</sup> on day 14 with administration after food intake, the peak plasma concentrations (C<sub>max </sub>in &micro;g/ml) for capecitabine, 5&#39;-DFCR, 5&#39;-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively. The time to peak plasma concentrations (T<sub>max </sub>in hours) were 1.50, 2.00, 2.00, 2.00 and 3.34. The AUC<sub>0-&infin;</sub> values in &mu;g<sup>&bull;</sup>h/ml were 7.75, 7.24, 24.6, 2.03 and 36.3.</p><p>Distribution&nbsp;</p><p><em>In vitro</em> human plasma studies have determined that capecitabine, 5&#39;-DFCR, 5&#39;-DFUR and 5-FU are 54%, 10%, 62% and 10% protein bound, mainly to albumin.&nbsp;</p><p>Biotransformation&nbsp;</p><p>Capecitabine is first metabolised by hepatic carboxylesterase to 5&#39;-DFCR, which is then converted to 5&#39;-DFUR by cytidine deaminase, principally located in the liver and tumour tissues. Further catalytic activation of 5&#39;-DFUR then occurs by thymidine phosphorylase (ThyPase). The enzymes involved in the catalytic activation are found in tumour tissues but also in normal tissues, albeit usually at lower levels. The sequential enzymatic biotransformation of capecitabine to 5-FU leads to higher concentrations within tumour tissues. In the case of colorectal tumours, 5-FU generation appears to be in large part localised in tumour stromal cells. Following oral administration of capecitabine to patients with colorectal cancer, the ratio of 5-FU concentration in colorectal tumours to adjacent tissues was 3.2 (ranged from 0.9 to 8.0). The ratio of 5-FU concentration in tumour to plasma was 21.4 (ranged from 3.9 to 59.9, n=8) whereas the ratio in healthy tissues to plasma was 8.9 (ranged from 3.0 to 25.8, n=8). Thymidine phosphorylase activity was measured and found to be 4 times greater in primary colorectal tumour than in adjacent normal tissue. According to immunohistochemical studies, thymidine phosphorylase appears to be in large part localised in tumour stromal cells.</p><p>5-FU is further catabolised by the enzyme dihydropyrimidine dehydrogenase (DPD) to the much less toxic dihydro-5-fluorouracil (FUH<sub>2</sub>). Dihydropyrimidinase cleaves the pyrimidine ring to yield 5-fluoro-ureidopropionic acid (FUPA). Finally, &beta;-ureido-propionase cleaves FUPA to &alpha;fluoro-&beta;-alanine (FBAL) which is cleared in the urine. Dihydropyrimidine dehydrogenase (DPD) activity is the rate limiting step. Deficiency of DPD may lead to increased toxicity of capecitabine (see section 4.3 and 4.4).&nbsp;</p><p>Elimination&nbsp;</p><p>The elimination half-life (t<sub>1/2 </sub>in hours) of capecitabine, 5&#39;-DFCR, 5&#39;-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively. Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Faecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL, which represents 57% of the administered dose. About 3% of the administered dose is excreted in urine unchanged</p><p>Combination therapy&nbsp;</p><p>Phase I studies evaluating the effect of capecitabine on the pharmacokinetics of either docetaxel or paclitaxel and vice versa showed no effect by capecitabine on the pharmacokinetics of docetaxel or paclitaxel (C<sub>max</sub> and AUC) and no effect by docetaxel or paclitaxel on the pharmacokinetics of 5&#39;-DFUR.</p><p>Pharmacokinetics in special populations&nbsp;</p><p>A population pharmacokinetic analysis was carried out after capecitabine treatment of 505 patients with colorectal cancer dosed at 1250 mg/m<sup>2</sup> twice daily. Gender, presence or absence of liver metastasis at baseline, Karnofsky Performance Status, total bilirubin, serum albumin, ASAT and ALAT had no statistically significant effect on the pharmacokinetics of 5&#39;-DFUR, 5FU and FBAL.&nbsp;</p><p><em><u>Patients with hepatic impairment due to liver metastases:</u></em> According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment. There are no pharmacokinetic data on patients with severe hepatic impairment.</p><p><em><u>Patients with renal impairment</u>:</em> Based on a pharmacokinetic study in cancer patients with mild to severe renal impairment, there is no evidence for an effect of creatinine clearance on the pharmacokinetics of intact drug and 5-FU. Creatinine clearance was found to influence the systemic exposure to 5&#39;-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%). FBAL is a metabolite without antiproliferative activity.&nbsp;</p><p><em><u>Elderly:</u></em> Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5&#39;-DFUR and 5-FU. The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL). This increase is likely due to a change in renal function.</p><p><em><u>Ethnic factors:</u></em> Following oral administration of 825 mg/m<sup>2</sup> capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower C<sub>max</sub> and 24% lower AUC for capecitabine than Caucasian patients (n=22). Japanese patients had also about 25% lower C<sub>max</sub> and 34% lower AUC for FBAL than Caucasian patients. The clinical relevance of these differences is unknown. No significant differences occurred in the exposure to other metabolites (5&#39;-DFCR, 5&#39;-DFUR, and 5-FU).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat-dose toxicity studies, daily oral administration of capecitabine to cynomolgus monkeys and mice produced toxic effects on the gastrointestinal, lymphoid and haemopoietic systems, typical for fluoropyrimidines. These toxicities were reversible. Skin toxicity, characterised by degenerative/regressive changes, was observed with capecitabine. Capecitabine was devoid of hepatic and CNS toxicities. Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m<sup>2</sup>/day).</p><p>A two-year mouse carcinogenicity study produced no evidence of carcinogenicity by capecitabine.&nbsp;</p><p>During standard fertility studies, impairment of fertility was observed in female mice receiving capecitabine; however, this effect was reversible after a drug-free period. In addition, during a 13-week study, atrophic and degenerative changes occurred in reproductive organs of male mice; however these effects were reversible after a drug-free period (see section 4.6).</p><p>In embryotoxicity and teratogenicity studies in mice, dose-related increases in foetal resorption and teratogenicity were observed. In monkeys, abortion and embryolethality were observed at high doses, but there was no evidence of teratogenicity.</p><p>Capecitabine was not mutagenic <em>in vitro </em>to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay). However, similar to other nucleoside analogues (ie, 5FU), capecitabine was clastogenic in human lymphocytes (<em>in vitro</em>) and a positive trend occurred in mouse bone marrow micronucleus tests (<em>in vivo</em>).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypromellose 2910 5cps (Methocel E5 LV Premium), Microcrystalline cellulose (Avicel PH 112), Anhydrous Lactose (Super tab 21 AN), Croscarmellose Sodium (Ac-Di-Sol), Magnesium stearate, Purified water.</p><p>film Coating Composition: HPMC 2910/ Hypromellose, Titanium Dioxide, Iron oxide red, Iron oxide yellow Talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>500mg : 12 X 10&rsquo;s Alu-Alu blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                .  Saudi Hetero Lab Co, Ltd. 
     Aljameah Street, Malaz quarter, Riyadh 11441 
     Saudi Arabia 
     Tel: +966 11 477 2215
      Manufacture: 
     Hetero Lab Unit V, Hyderabad, India  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/01/2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>